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towards β-methyl azalanthionines, by ring-opening of N-activated aziridine-2-
carboxylates 
 
Keith O’Brien, Keith ó Proinsias and Fintan Kelleher* 
 
 Molecular Design and Synthesis Group, Centre of Applied Science for Health, 
Institute of Technology Tallaght, Dublin 24, Ireland. 
 
Abstract: 
Orthogonally protected azalanthionines were successfully synthesised by the ring-
opening of N-activated aziridine-2-carboxylates with protected diaminopropanoic 
acids (DAPs). The required DAPs were also prepared by ring-opening of N-activated 
aziridine-2-carboxylates with para-methoxybenzylamine, but it was found that the 
choice of aziridine protecting groups dictated both the success of the reaction as well 
as the regioselectivity of the isolated products. Attempts to extend the methodology to 
the preparation of the more sterically demanding β-methyl azalanthionines have, so 
far, been unsuccessful. 
 
Keywords: 
1,2-Diaminopropanoic acids (DAPs); Lanthionine; Aziridine-2-carboxylates; Ring-
opening; Azalanthionines; β-Methyl azalanthionines. 
 
1. Introduction 
The incorporation of amino acid cross-linkers into peptide structures, which leads to 
the formation of cyclic peptides, is an important way that nature uses to give defined 
peptide and protein conformations with high biological activity.  Importantly the 
stability of the peptides can also be increased due to their increased resistance to 
proteolytic cleavage.1 There are many such cross-linkers in nature including 
lysinoalanine and histidinoalanine,2 while the lanthipeptides contain the lanthionine or 
β-methyllanthionine cross-linking amino acids (Figure 1).3 Nisin is one of the most 
studied lanthipeptides and is a highly active antimicrobial peptide which has been 
used worldwide for decades as a food preservative (E234). The chemical synthesis of 
orthogonally protected lanthionines and β-methyllanthionines has been studied 
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extensively.4 Vederas has also reported on the replacement of the thioether bridge of 
lanthionines and β-methyllanthionines with both carbon chain and oxygen bridged 
analogues.5  
 
NH2
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H
H2N
HO2C NH2
CO2HN
H
H2N
HO2C
Me
Azalanthionine β-Methyl azalanthionine
NH2
CO2HSH2N
HO2C NH2
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Me
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NH2
CO2HN
H
H2N
HO2C
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4
NH2
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HO2C
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N
SR SR
RSS
S
R
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Figure 1. Structures of some cross-linking amino acids2,3 
 
We recently reported on our preliminary studies on extending the range of lanthionine 
thioether bridge replacements that are available by preparing orthogonally protected 
azalanthionines, which have an amine linker which should have quite different 
physicochemical properties to any of the other analogues (lanthionines, 
oxalanthionines or carbalanthionines), including water solubility at physiological pH.6 
To date this is the only reported method for the preparation of orthogonally protected 
azalanthionines though a small number of reports on the synthesis of azalanthionines 
are known, but none gave orthogonally protected compounds which would be suitable 
for use in solid-phase peptide synthesis.7 The presence of a nitrogen atom in the cross-
linker would also provide a very useful handle for further derivatisation, or 
conjugation, where required.  
 
Thus, the goals of the current study were firstly to extend the range of orthogonally 
protected azalanthionines using our previously developed aziridine ring opening 
methodology. Our initial report demonstrated the viability of the methodology but 
only one azalanthionine analogue was prepared with the correct stereochemistry, 
when compared to stereochemistry of natural lanthionine containing peptides. For the 
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future incorporation of azalanthionines, in order to prepare lantibiotic analogues, a 
number of differentially protected analogues would be required with the desired 
stereochemistry. Since many lanthipeptides also contain the β-methyllanthionine 
moiety, the second goal of this study was the extension of the methodology to prepare 
a range of β-methyl azalanthionines, again with the correct stereochemistry at each 
stereocentre. 
 
2. Results and Discussion 
2.1 Synthesis of orthogonally protected azalanthionines 
The retrosynthetic analysis of the orthogonally protected azalanthionines shows that 
they could be prepared by ring-opening of N-activated aziridine-2-carboxylates with 
protected diaminopropionic acids (DAPs) (Figure 2).  In turn the DAPs could be 
obtained by ring-opening of differently protected aziridines with p-
methoxybenzylamine.  
 
NHP4
CO2P3N
P5
P1HN
P2O2C
P = Protecting group
N
P1 NHP
4
CO2P3N
H
P5
+
P2O2C
N
P4
CO2P3
P5 NH2 +
SR SR S
 
Figure 2. Retrosynthetic analysis of orthogonally protected azalanthionines 
 
In order to prepare a range of different orthogonally protected azalanthionines suitable 
for solid-phase peptide synthesis the precursor N-activated aziridine-2-carboxylates 
were first prepared to explore the optimal substitution patterns for the synthesis of the 
required DAPs (Scheme 1). Starting with the known N-trityl aziridine-2-carboxylates, 
1a and 1b,8 replacement of the trityl group with a number of electron-withdrawing 
groups gave the required N-activated aziridines (2a-2c, 3a-3c and 7). The 
regioselectivity of the ring-opening reaction, on treatment of the N-activated 
aziridines with p-methoxybenzylamine, was highly dependent on both the nature of 
the N-substituent and the ester group in the 2-position, as well as the temperature of 
the reaction.9 In all cases two molar equivalents of p-methoxybenzylamine was used.  
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2a, P = Ts
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3b, P = p-Ns
3c, P = p-Nz
4a, P = Ts
4b, P = p-Ns
4c, P = p-Nz
5a, P = Ts
5b, P = p-Ns
6c, P = p-Nz
N
Alloc
CO2All
7
N P
H
Reagents and conditions; (a) See Supporting Information; (b) p-methoxybenzylamine (2 molar equiv.), MeCN, rt, 24 h.
b
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Scheme 1. Synthesis of 1,2-diaminopropanoic acid derivatives (4-6) 
 
N
EWG
CO2R
αβ
+
H2N
OMe NHEWG
CO2RN
H
PMB
+
HN
CO2RN
H
EWG
PMB
β-attack α-attack
CH3CN
 24 h
(2 molar equiv.)
S S R
 
Entry Aziridine Temp (oC) % β-attacka % α-attacka 
1 
2 
2a (R = Me, EWG = Ts) 
 
25 
80 
70 (4a) 
32 (4a) 
23 (5a) 
41 (5a) 
3 2b (R = Me, EWG = p-Ns) 25 42 (4b) 32 (5b)  
4 2c (R = Me, EWG = p-Nz) 25 63 (4c) - 
5 3a (R = Allyl, EWG = Ts) 25 or 80 b - - 
6 3b (R = Allyl, EWG = p-Ns) 25 or 80 b - - 
7 3c (R = Allyl, EWG = p-Nz) 25 66 (6c) - 
10 7 (R = Allyl, EWG = alloc) 25 or 80 b - - 
a
 Product number is in parantheses; bNo product from α- or β-attack obtained, even in 
the presence of BF3.OEt2 as Lewis acid catalyst. 
 
Table 1. Regioselectivity of the ring-opening of N-activated aziridine-2-
carboxylates with p-methoxybenzylamine
 
 
Aziridine 2a gave a mixture of 4a and 5a in a 70:23 ratio at room temperature (Table 
1, entry 1). However, the selectivity was reversed to give 4a and 5a in a 32:41 ratio, 
when the reaction was conducted at 80 oC (entry 2). Further reactions in this series 
were conducted at room temperature to maximise the yield of the product obtained 
from attack at the aziridine β-position. It was found that the p-Ns aziridine 2b gave 4b 
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and 5b in a 63:21 ratio (entry 3). However, the p-Nz substituted aziridine 2c only 
gave 4c, the product of attack at the less hindered β-carbon of the aziridine in a 66% 
yield (entry 4). For the N-activated aziridine allyl esters 3a-c (entries 5-7), only the N-
p-Nz substituted derivative 3c underwent reaction with p-methoxybenzylamine, with 
6c being obtained in a 66% yield, as the sole product. The N-alloc activated aziridine 
7 gave no product from attack by p-methoxybenzylamine (entry 10). For the 
unsuccessful reactions, use of Lewis acid catalysis (boron trifluoride etherate) and/or 
heating to 80 oC, did not lead to any of the desired products. An examination of the 
results of the ring-opening reactions shows that the regioselective outcome is not 
predictable.9 
 
Having prepared a number of the required DAPs they were then used to prepare 
orthogonally protected azalanthionines by ring-opening of the protected N-activated 
aziridines (Scheme 2). In these cases, it was found that there was no reaction observed 
at 25 oC, in the presence of 2 molar equivalents of the DAP. When the reactions were 
heated to 80 oC, only products from attack at the less sterically hindered aziridine β-
position were obtained. It is most likely that this is due to the increased steric bulk of 
the secondary amine nucleophile of the DAP compared to the primary amino group of 
the p-methoxybenzylamine. Thus far a range of six diastereoisomeric azalanthionines 
(8-12, 17) have been prepared using this methodology, with the stereochemistry of the 
diastereoisomer depending on whether L- or D-serine was used as the starting material 
for the precursor N-activated aziridines (Scheme 2 and Table 2).  
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NHTs
CO2MeN
H
PMB
4a
NHp-Nz
CO2AllN
PMB
TsHN
MeO2C
10
NHp-Nz
CO2AllN
PMB
p-NsHN
MeO2C
11
Reagents and conditions; (a) 2b (0.5 molar equiv.), MeCN, 80 oC, 24 h, (for 9 using R-2b (0.5 molar 
equiv.)); (b) 2a (0.5 molar equiv.), MeCN, 80 oC, 24 h; (c) 2b (0.5 molar equiv.), MeCN, 80 oC, 24 h, (for 12 
using R-2b (0.5 molar equiv.)); (d) i) TMS-Cl, Et3N, DCM: ii) Trt-Cl, Et3N, MeOH, 58%; (e) i) Cs2CO3, MeOH:
 ii) allyl bromide, DMF, 91%;(f) Ref 10; (g) thiophenol, K2CO3, DMF, rt, 16 h, 80%; (h) 2a, BF3.OEt2, CH2Cl2, 
rt, 24 h, 30%.
a
NHTs
CO2MeN
PMB
p-NsHN
MeO2C
8
NHTs
CO2MeN
PMB
p-NsHN
MeO2C
9
NHp-Nz
CO2AllN
H
PMB
6c
b
c
NHp-Nz
CO2AllN
PMB
p-NsHN
MeO2C
12
NHAlloc
CO2AllN
Ns
PMB
14
NHAlloc
CO2AllN
PMB
TsHN
MeO2C
17
NHAlloc
CO2AllN
H
PMB
NHTrt
CO2AllHO
1516
d e
f
S
S S S
SS S
S S S
SS S S
S
R
R
13
NHTrt
CO2HHO S
L-Serine
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Scheme 2. Synthesis of azalanthionines (8-12, 17) 
NHP2
CO2R2N
H
PMB
N
P1
CO2R1
S
+
NHP2
CO2R1N
PMB
P1HN
R1O2C
S80 oC
CH3CN
2 molar equivalents
 
Entry Aziridine DAP % Azalanthioninea 
1 
2 
S-2b (R1 = Me, P1 = p-Ns) 
R-2b (R1 = Me, P1 = p-Ns) 
4a (R2 = Me, P2 = Ts) 46 (8, (S,S)) 
51(9, (R,S)) 
3 S-2a (R1 = Allyl, P1 = p-Nz) 6c (R2 = Me, P2 = p-Ns) 38 (10, (S,S)) 
4 
5 
S-2b (R1 = Me, P1 = p-Ns) 
R-2b (R1 = Me, P1 = p-Ns) 
6c (R2 = Me, P2 = p-Ns) 27 (11, (S,S)) 
32 (12, (R,S)) 
a
 % yield and stereochemistry in parantheses; 
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Table 2. Synthesis of orthogonally protected azalanthionines 8-12 
 
The isolated yields of the azalanthionines, after aqueous workup, were 27-51%, which 
are comparable with those obtained for similar aziridine ring-opening reactions with 
protected cysteine or serine nucleophiles, used to prepare orthogonally protected 
lanthionines11 and oxalanthionines.5b,c The mass balance in each case was made up of 
the starting DAP and numbers of unidentified products which resembled ring-opened 
aziridines. These were possibly serine derivatives, though none were conclusively 
identified, either by NMR or mass spectrometric analysis. It also is worth mentioning 
that all of the synthesised azalanthionines were prone to decomposition when stored at 
ambient temperature. Simple TLC and HPLC analysis showed that they all 
decomposed to a multitude of products, particularly when stored in solution (results 
not shown).  It was necessary to store them free of solvent in a freezer at -20 oC in 
order to increase their stability, but even in these cases they had almost completely 
decomposed in a matter of weeks. The reason for the instability is most likely due to 
the strongly electron-withdrawing protecting groups present on the nitrogen atoms, 
which increases the acidity of the α-hydrogens. This makes the molecules more prone 
to elimination most likely by a retro-Michael mechanism. Therefore, the same 
electron-withdrawing groups that are necessary for activation of the aziridine ring to 
nucleophilic ring-opening are also responsible for the instability of the resulting 
products. 
 
Azalanthionine 12 is considered the most useful of those prepared, as it contained five 
orthogonal protecting groups. The next stage in the synthesis of aza analogues of 
lanthipeptides would involve the deprotection of N-p-Nz protecting group of 12 and 
replacement with a Fmoc group. Removal of the allyl group of the ester, with 
Pd(PPh3)4, would then give a carboxylic acid which could be attached to a resin for 
solid-phase peptide synthesis. Both of these deprotections have been successfully 
achieved by Vederas in the synthesis of analogues of the lanthipeptide lacticin 3147 
A2, containing oxalanthionine linkers, so it is felt that these particular deprotections 
should also be possible for azalanthionine 12. Furthermore the deprotection of the N-
Ns group of DAP 15, with thiophenol, has already been shown in the preparation of 
DAP 14, in an isolated yield of 80% (Scheme 2). 
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As well as synthesising the azalanthionines two of the isomeric nor-azalanthionines 
(18 and 19) were also prepared (Scheme 3). This was achieved by treating the same 
N-activated aziridine-2-carboxylates (2a and 2b) with the β-amino acid 5a, which had 
been obtained as a by-product from attack of p-methoxybenzylamine at the α-position 
of the aziridines (Scheme 1). Again, in these cases, only attack at the less hindered β-
position occurred to give nor-azalanthionines 18 and 19, in 47% and 39% yields, 
respectively. The success of these reactions was somewhat surprising because of the 
highly hindered nature of the secondary amine nucleophiles used. 
Reagents and conditions; (a) 2a (2 molar equiv.), MeCN, 80 oC,
 24 h, 47%; (b) 2b (2 molar equiv.), MeCN, 80 oC, 24 h, 39%;
HN CO2Me
PMB
5a
N Ts
H
a
N CO2Me
PMB
N Ts
H
p-NsHN
MeO2C
18
b
N CO2Me
PMB
N Ts
H
p-NsHN
AllO2C
19
S
S
R
R
R
 
Scheme 3. Synthesis of isomeric nor-azalanthionines (18 and 19) 
  
2.2 Routes towards β-methyl azalanthionines 
Having successfully prepared orthogonally protected azalanthionines attempts were 
then made to extend the methodology to the β-methyl azalanthionines, which are the 
amine-linked analogues of the known β-methyllanthionines and β-methyl 
oxalanthionines.5 For the retrosynthesis of the β-methyl azalanthionines two simple 
disconnections were envisaged (Figure 3). Disconnection A would give a route 
involving ring-opening of N-activated 3-methyl-aziridine-2-carboxylates with the 
previously prepared DAP derivatives. The aziridines would come from suitably 
protected threonine derivatives, as starting materials. The alternative disconnection B 
would give N-activated 3-unsubstituted-aziridine-2-carboxylates and β-methyl DAPs. 
It was envisaged that the required β-methyl DAPs would, in turn, be prepared by ring-
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opening of N-activated 3-methyl-aziridine-2-carboxylates with p-
methoxybenzylamine. 
 
NHP4
CO2P3N
P5
P1HN
P2O2C
P = Protecting group
N
P1 NHP4
CO2P3N
H
P5+
P2O2C
N
P4
CO2P3
P5 NH2
+
Me
A
B
A
Me
NH
P5
P1HN
P2O2C
Me
N
P1
P2O2C Me
+
B
R
R
S
S
S
R R
RR
 
Figure 3. Retrosynthetic analysis of orthogonally protected β-methyl 
azalanthionines 
 
Thus, the N-activated 3-methyl-aziridine-2-carboxylates were prepared in a similar 
manner to their des-3-methyl counterparts, with L-threonine being used in place of L-
serine, as the starting material (Scheme 4). The N-trityl aziridine methyl and allyl 
esters (20a and 20b) were synthesised from L-threonine in good yield.8 The trityl 
group, of each ester was removed and replaced with activating groups to promote 
aziridine ring-opening. The groups used were Ts, p-Ns and p-Nz, all of which had 
been successfully used previously in the synthesis of the azalanthionines (vide supra). 
In all this gave six different activated aziridines (21a-c and 22a-c) which were then 
used for the synthesis of β-methyl azalanthionines.  
 
The ring-opening reactions were attempted using the previously successful conditions 
of stirring at reflux temperature in acetonitrile using a suitably protected DAP. The 
DAP chosen was 6c which was used successfully in the preparation of the 
corresponding azalanthionines. However, none of the desired β-methyl 
azalanthionines were obtained, with only the unreacted DAP and unidentified 
products being recovered that appeared, from their 1H NMR spectra, to be derived 
from ring-opening of the 3-methyl-aziridine-2-carboxylates. Use of Lewis acid 
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catalysis, with BF3.OEt2 in dichloromethane at reflux temperature, again gave none of 
the required products.  
 
Using the successful synthesis of the nor-azalanthionines by ring-opening of an 
aziridine with a relatively hindered secondary amine as a model, the synthesis of the 
β-methyl azalanthionines was then attempted by reaction of β-methyl DAPs with N-
activated 3-unsubstituted aziridines. The β-methyl DAPs were prepared by ring-
opening of the β-methyl aziridines (21a-c and 22a-c) with p-methoxybenzylamine 
(Scheme 4). For example, when aziridine 21a was reacted with p-
methoxybenzylamine (2 molar equivalents) at room temperature in acetonitrile, again 
two regioisomers were obtained in a combined yield of 76% (Table 3, entry 2). In this 
case almost equal amounts of both regioisomers were isolated, with the product from 
β-attack (23a) being obtained in 41%, while that from α-attack (24a) was obtained in 
35% yield. When the reaction was repeated at reflux temperature the ratio was ~4:1 in 
favour of the product from α-attack (entry 3). When the reaction was conducted at 0 
oC, the ratio was ~1:1 (entry 1, 34% for β-attack and 32% for α-attack). All the other 
N-activated 3-methyl aziridines previously synthesised were then reacted with p-
methoxybenzylamine at different temperatures (Table 3). 
N
Trt
CO2R
NHP
CO2AllN
H
PMB20a, R = Me
20b, R = Allyl
Reagents and conditions; (a) Ref 8; (b) see Scheme 2; (c) p-methoxybenzylamine (2 molar equiv.), MeCN, 24 h.
c
b
N
P
CO2All
NHP
CO2MeN
H
PMB
+ HN CO2Me
PMB
c
N
P
CO2Me
or
21a, P = Ts
21b, P = p-Ns
21c, P = p-Nz
22a, P = Ts
22b, P = p-Ns
22c, P = p-Nz
23a, P = Ts
23b, P = p-Ns
24a, P = Ts
24b, P = p-Ns
N P
H
L-Threonine
a
+ HN CO2All
PMB
N P
H
25a, P = Ts
25b, P = p-Ns
25c, P = p-Nz
26b, P = p-Ns
SS
S S
S S S
S
R
R
S
R
R
S
 
Scheme 4. Synthesis of β-methyl DAPs 
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N
EWG
CO2R
αβ
+
H2N
OMe NHEWG
CO2RN
H
PMB
+
HN
CO2RN
H
EWG
PMB
β-attack α-attack
CH3CN
 24 h
SS S
R
R
S
2 molar equiv.
 
Entry Aziridine Temp (oC) % β-attacka % α-attacka 
1 
2 
3 
21a (R = Me, EWG = Ts) 
 
0 
25 
80 
34 (23a) 
41 (23a) 
15 (23a) 
32 (24a)  
35 (24a) 
62 (24a) 
4 
5 
6 
19b (R = Me, EWG = p-Ns) 
 
0 
25 
80 
42 (23b) 
27 (23b) 
21 (23b) 
32 (24b)  
55 (24b) 
61 (24b) 
7 19c (R = Me, EWG = p-Nz) NRb - - 
8 
9 
10 
20a (R = Allyl, EWG = Ts) 0 
25 
80c 
38 (25a) 
42 (25a) 
- 
- 
- 
- 
11 
12 
13 
20b (R = Allyl, EWG = p-Ns) 0 
25 
80c 
43 (25b) 
21 (25b) 
- 
35 (26b) 
49 (26b) 
- 
14 
15 
16 
20c (R = Allyl, EWG = p-Nz) 0 
25 
80c 
39 (25c) 
27 (25c) 
- 
- 
- 
- 
a
 Product number is in parantheses; b No reaction when conducted at 0 oC, 25 oC or 80 
oC; cNo product from α- or β-attack obtained. 
 
Table 3: Regioselectivity of the ring-opening of 3-methyl-aziridines with p-
methoxybenzylamine
 
 
When aziridine 21b was used similar results were obtained (entries 4-6), except for 
the reaction conducted at 25 oC, where the product of α-attack (55% 24b) was 
obtained in preference to the product of β-attack (27%, 23b). Surprisingly, when 
aziridine 21c, which contains the N-p-Nz group, was used no products from attack at 
either the α- or β-positions were obtained at any of the temperatures studied (entry 7). 
This is in contrast to our previous study which showed that the 3-unsubstituted N-p-
Nz aziridine methyl ester (2c) gave the product from attack at the β-position (4c) as 
the sole product in a 63% isolated yield.9 This study had found that when the ester 
group was changed from methyl to allyl only the 3-unsubstituted aziridine with a N-p-
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Nz activating group underwent a ring-opening reaction with p-methoxybenzylamine, 
giving the product of β-attack (6c) as the sole product in 66% yield. However, when 
the corresponding 3-methyl substituted aziridines were used strikingly different 
results were obtained (entries 8-16). In all cases, reactions conducted at 80 oC did not 
give any products from attack at the α or β positions. For aziridines 22a and 22c only 
β-attack was observed, but for 22b products from both α- and β-attack were isolated. 
As for the case of the 3-unsubstituted aziridines the regioselectivity is highly 
unpredictable. A computational study of both the 3-substituted and 3-unsubstituted 
aziridine derivatives is currently being undertaken in order to try to explain the 
observed regioselectivity outcomes. 
 
With a selection of the required β-methyl DAPs (23a, 23b, 25a-c) in hand, an attempt 
was made to ring-open the 3-unsubstituted aziridines (2a-c and 3a-c) under reflux 
conditions in acetonitrile. A significant number of different combinations were tried 
but there was no evidence, in any case, for the desired β-methyl azalanthionines. In 
every reaction only the starting β-methyl DAPs were recovered after aqueous workup, 
along with compounds which appeared to be derived from opening of the aziridine 
ring, as evidenced by the appearance of their NMR spectra compared with, for 
example, aziridine ring-opened precursors. As before, the use of BF3.OEt2 in 
dichloromethane at reflux temperature was also unsuccessful. These results were 
somewhat surprising owing to the successful synthesis of the nor-lanthionines 18 and 
19, using what appeared to be an even more sterically demanding secondary amine 
nucleophile. 
 
3. Conclusions 
 
The synthesis of a range of orthogonally protected azalanthionines, which are amine 
linked analogues of the increasingly important lanthionine-containing bioactive 
peptides, has been achieved by ring opening of N-activated 3-unsubstituted aziridines 
with protected DAPs. However, the azalanthionines are unstable to storage at ambient 
temperature, most probably due to the strongly electron-withdrawing nitrogen 
substitutents. Extension of the methodology to the preparation of β-methyl 
azalanthionines has not been achieved so far. This was attempted by two methods 
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which involved i) reaction of DAPs with N-activated 3-methyl-substituted aziridines, 
or ii) reaction of β-methyl DAPs with N-activated 3-unsubstituted aziridines. In all 
cases, there was no indication of the formation of desired β-methyl azalanthionines, 
even by mass spectrometry. It has also been found that the regioselectivity of the ring 
opening of N-activated aziridine-2-carboxylates with p-methoxybenzylamine is not 
predictable. 
 
4. Experimental 
 
4.1 General 
All isolated products were purified using column chromatography with silica gel 
(Aldrich, 70-230 mesh, 60 Å) in the indicated solvent systems. Melting points were 
determined with Stuart scientific SMP1 & Mettler FP62 melting point apparatus. 
Analytical thin layer chromatography (TLC) was performed on pre-coated plates 
(Merck Kieselgel 60 F254) and visualised with UV light (254 nm), iodine vapour or 
aqueous potassium permanganate solution. Infrared spectra were recorded as KBr 
disks or a thin film between sodium chloride plates, on Avatar 320 and Nicolet impact 
410 FT-IR spectrophotometers, run on EZ Omnic E.S.P 5.2a and 3.1a software 
packages, respectively. Polarimetry was carried out using an Optical Activity AA-55 
series polarimeter at ambient temperature with a 2 dm, 1 ml cell. 1H NMR and 13C 
NMR spectra were measured on a JOEL JNM-LA300 FT-NMR or a Bruker Avance 
III 500 MHz FT-NMR with TopSpin 2.16 Software and 5mm PATXI 1H/13-C/15N 
Z-GRD probe, in CDCl3 as solvent. Chemical shift values are reported relative to 
tetramethylsilane. Mass Spectrometry was carried out at the Centre for Synthesis and 
Chemical Biology in University College Dublin using Quattro microTM LC-MS/MS 
and Liquid chromatography time-of-flight (LCT) mass spectrometers. Exact Mass 
Spectrometry analyses were carried out at the Department of Chemistry, NUI 
Maynooth, Co. Kildare, Ireland.  
 
Experimental Procedures 4.2 
General procedure for ring-opening of aziridines with p-methoxybenzylamine 
for the preparation of DAPs 4a-c and 6c. 
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To a solution of the relevant aziridine (2 mmol) in acetonitrile (5 ml) was added p-
methoxybenzylamine (0.52 ml, 4 mmol) and the solution was stirred for 24 h at room 
temperature. The solvent was removed in vacuo, and then the residue was redissolved 
in ethyl acetate (20 ml), washed with brine (2 x 20 ml), dried over anhydrous 
magnesium sulfate and concentrated in vacuo. The crude product was purified by 
flash column chromatography on silica gel in petroleum ether:ethyl acetate (2:1). 
 
(S)-Methyl 3-(4-methoxybenzylamino)-2-(4-methylphenylsulfonamido) propanoate 
(4a). Colourless oil (0.54 g, 70%); Rf: 0.12 petroleum ether:ethyl acetate (1:1); [α]D20 = 
+13.35o (c 1.0 in CHCl3);  1H NMR (CDCl3, δ ppm) 7.72 (d, 2H, J = 8.8 Hz), 7.28 (d, 
2H, J = 8.8 Hz), 7.16 (d, 2H, J = 8.8 Hz), 6.85 (d, 2H, J = 8.8 Hz), 4.03 (t, 1H, J = 4.8 
Hz),  3.79 (s, 3H), 3.65 (d, 1H, J = 12.9 Hz), 3.61 (d, 1H, J = 12.9 Hz), 3.52 (s, 3H), 
2.88 (d, 2H, J = 5.2 Hz), 2.40 (s, 3H); 13C NMR (CDCl3, δ ppm) 171.2, 158.7, 143.7, 
136.6, 131.3, 129.6, 129.3, 127.2, 113.8, 60.4, 55.3, 52.6, 52.3, 50.0, 21.5; IR (thin 
film, cm-1)  3347, 3089, 2981, 1744, 1188, 1150;  HRMS (ES+) calculated for 
C19H25N2O5S, [M+H]+ 393.1479, found [M+H]+ 393.1477. 
 
(S)-Methyl 3-(4-methoxybenzylamino)-2-(4-nitrophenylsulfonamido) propanoate (4b).  
Pale yellow oil (0.53 g, 42%); Rf: 0.20 petroleum ether:ethyl acetate (1:1); [α]D20 = 
+16.51o (c 1.0 in CHCl3);  1H NMR (CDCl3, δ ppm) 8.32 (d, 2H, J = 9.0 Hz), 8.02 (d, 
2H, J = 9.0 Hz), 7.16 (d, 2H, J = 8.7 Hz), 6.86 (d, 2H, J = 8.7 Hz), 4.11 (t, 1H, J = 6.1 
Hz), 3.80 (s, 3H), 3.65 (s (br), 2H), 3.58 (s, 3H), 3.01-2.86 (dd, 2H, J = 5.0, 4.9 Hz); 
13C NMR (CDCl3, δ ppm) 170.7, 158.9, 150.0, 145.8, 131.2, 129.5, 128.3, 124.4, 
113.8, 55.5, 55.3, 52.8, 52.6, 49.9; IR (thin film, cm-1) 3375, 3087, 2981, 1743, 1552, 
1381, 1177; HRMS ( S+) calculated for C18H22N3O7S, [M+H]+ 438.1329, found 
[M+H]+ 438.1322. 
 
(S)-Methyl 3-(4-methoxybenzylamino)-2-((4-nitrobenzyloxy)carbonylamino) 
propanoate (4c). Pale yellow oil (0.46 g, 63%); Rf: 0.22 petroleum ether:ethyl acetate 
(1:1); [α]D20 = +22.48o (c 1.0 in CHCl3); 1H NMR (CDCl3, δ ppm) 8.20 (d, 2H, J = 8.7 
Hz), 7.50 (d, 2H, J = 8.7 Hz), 7.20 (d, 2H, J = 8.6 Hz), 6.86 (d, 2H, J = 8.6 Hz), 5.19 
(d, 2H, J = 8.6 Hz), 4.43 (m, 1H), 3.78 (s, 3H), 3.75 (s (br), 2H), 3.72 (s, 3H), 3.10-
2.98 (dd, 2H, J = 4.8, 4.8 Hz); 13C NMR (CDCl3, δ ppm) 171.3, 158.8, 155.3, 147.5, 
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143.6, 130.9, 129.5, 128.0, 123.7, 113.6, 65.3, 55.1, 53.5, 52.6, 52.3, 49.1; IR (thin 
film, cm-1) 3341, 3065, 2981, 1744, 1680, 1212; HRMS (ES+) calculated for 
C20H24N3O7, [M+H]+ 418.1609, found [M+H]+ 418.1627. 
 
(R)-Methyl 2-(4-methoxybenzylamino)-3-(4-methoxyphenylsulfonamido) propanoate 
(5a). Colourless oil (0.17 g, 41%); Rf: 0.24 petroleum ether:ethyl acetate (1:1); [α]D20 
= +12.41o (c 1.0 in CHCl3);  1H NMR (CDCl3, δ ppm) 7.70 (d, 2H, J = 8.6 Hz), 7.28 
(d, 2H, J = 8.0 Hz), 7.15 (d, 2H, J = 8.6 Hz), 6.85 (d, 2H, J = 8.6 Hz), 5.15 (s (br), 
1H) 3.80 (s, 3H), 3.68 (s, 3H), 3.65 (m, 2H), 3.51(d, 1H, J = 12.9 Hz), 3.30 (m, 1H), 
3.26 (dd, 1H, J = 8.6, 8.6  Hz), 2.95 (dd, 1H,  J = 7.5, 7.4 Hz); 13C NMR (CDCl3, δ 
ppm) 172.9, 158.9, 143.5, 136.6, 131.0, 129.7, 129.4, 127.0, 113.9, 59.0, 55.3, 52.3, 
51.2, 44.2, 21.5; IR (thin film, cm-1) 3359, 3082, 2991, 1743, 1224, 1124. 
 
(R)-Methyl 2-(4-methoxybenzylamino)-3-(4-nitrophenylsulfonamido) propanoate (5b). 
Pale yellow oil (0.17 g, 32%); Rf: 0.32 petroleum ether:ethyl acetate (1:1); 1H NMR 
(CDCl3, δ ppm) 8.28 (d, 2H, J = 9.0 Hz), 7.94 (d, 2H, J = 9.0 Hz), 7.14 (d, 2H, J = 8.7 
Hz), 6.83 (d, 2H, J = 8.7 Hz), 3.80 (s, 3H), 3.71 (s, 3H), 3.65 (d, 1H, J = 12.9 Hz), 
3.54  (d, 1H, J = 12.9 Hz),  3.30-3.26 (m, 2H), 3.05 (m, 1H); 13C NMR (CDCl3, δ 
ppm) 172.5, 159.0, 149.9, 145.6, 130.8, 129.4, 128.2, 124.4, 113.9, 59.2, 55.5, 52.6, 
51.3, 44.3; IR (thin film, cm-1) 3401, 3065, 2971, 1745, 1542, 1371, 1196. 
 
(S)-Allyl 3-(4-methoxybenzylamino)-2-((4-nitrobenzyloxy) carbonylamino) 
propanoate (6c). Pale yellow oil (0.58 g, 66%); Rf: 0.11 petroleum ether:ethyl acetate 
(1:1); [α]D20 = +26.25o (c 1.0 in CHCl3); 1H NMR (CDCl3, δ ppm) 8.21 (d, 2H, J = 8.7 
Hz), 7.51 (d, 2H, J = 8.7 Hz), 7.19 (d, 2H, J = 8.6 Hz), 6.86 (d, 2H, J = 8.6 Hz), 5.89 
(m, 2H), 5.36-5.16 (m, 4H), 4.65 (d, 2H, J = 5.9 Hz), 4.43 (m, 1H), 3.79 (s, 3H), 3.70 
(s (br), 2H), 3.10-2.96 (dd, 2H, J = 5.8, 5.7 Hz); 13C NMR (CDCl3, δ ppm) 171.1, 
158.8, 155.6, 147.6, 143.8, 131.6, 131.4, 129.2, 128.0, 123.7, 118.9, 113.8, 66.1, 65.4, 
55.2, 54.1, 53.1, 49.5; IR (thin film, cm-1) 3367, 3075, 2976, 1743, 1674; HRMS 
(ES+) calculated for C22H26N3O7, [M+H]+ 444.1765, found [M+H]+ 444.1754. 
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(S)-Methyl 3-(((S)-3-methoxy-2-(4-methylphenylsulfonamido)-3-oxopropyl)(4-
methoxybenzyl)amino)-2-(4-nitrophenylsulfonamido) propanoate (8). N-p-nosyl 
aziridine methyl ester 2b (0.07 g, 0.25 mmol) was dissolved in MeCN (5 ml) before 
adding DAP 4a (0.2 g, 0.5 mmol, 2 eq.) and the solution was stirred at reflux 
temperature for 24 h before removing the solvent in vacuo. The oil was dissolved in 
ethyl acetate (20 ml), washed with brine (2 x 20 ml) and dried over anhydrous 
magnesium sulfate before removing the solvent in vacuo. The crude product was 
purified by preparative TLC on silica gel (petroleum ether:ethyl acetate 4:1)  to yield 
8, as a pale yellow oil (0.08 g, 46%). Rf:  0.37 petroleum ether:ethyl acetate (1:1); 1H 
NMR (CDCl3, δ ppm) 8.33 (d, 2H, J = 8.8 Hz), 8.07 (d, 2H, J = 8.8 Hz), 7.70 (d, 2H, 
J = 8.4 Hz), 7.32 (d, 2H, J = 8.3 Hz), 7.08 (d, 2H, J = 8.4 Hz), 6.80 (d, 2H, J = 8.4 
Hz), 6.20 (s (br), 1H), 4.19 (t, 1H, J = 5.3 Hz), 4.03 (dd, 2H, J = 7.8 Hz, 6.5 Hz) 3.79 
(s, 3H), 3.74 (d, 1H, J = 13.4 Hz), 3.50 (d, 1H, J = 13.4 Hz), 3.46 (s, 3H), 3.41 (s, 
3H), 2.97 (m, 3H), 2.71 (m, 1H), 2.40 (s, 3H); 13C NMR (CDCl3, δ ppm) 171.0, 
170.7, 159.0, 149.8, 146.3, 143.7, 136.5, 130.7, 130.5, 129.8, 128.5, 127.2, 124.1, 
113.9, 58.4, 56.7, 56.2, 55.1, 55.1, 52.68, 52.63, 21.6; IR (thin film, cm-1) 3356, 3089, 
2982, 1744, 1732, 1532, 1379,  1173, 1133. 
 
(S)-Methyl 3-(((R)-3-methoxy-2-(4-methylphenylsulfonamido)-3-oxopropyl)(4-
methoxybenzyl)amino)-2-(4-nitrophenylsulfonamido) propanoate (9). 9 was 
synthesised using a similar method to that used to synthesise 8, except the protected 
aziridine R-2b was used (0.07 g, 0.25 mmol). The crude product was purified by 
preparative TLC on silica gel (petroleum ether:ethyl acetate 4:1)  to yield 9 as a pale 
yellow oil (0.09 g, 51%). Rf: 0.18 petroleum ether:ethyl acetate (1:1); [α]D20 = +32.96o 
(c 1.0 in CHCl3); 1H NMR (CDCl3, δ ppm) 8.34 (d, 2H, J = 8.7 Hz), 8.06 (d, 2H, J = 
8.7 Hz), 7.73 (d, 2H, J = 8.4 Hz), 7.28 (d, 2H, J = 8.3 Hz), 7.13 (d, 2H, J = 8.5 Hz), 
6.82 (d, 2H, J = 8.5 Hz), 4.14 (d, 1H, J = 6.5 Hz), 4.06 (dd, 1H, J = 7.0, 6.2 Hz), 3.81 
(d, 1H, J = 12.9 Hz), 3.80 (s, 3H), 3.50 (d, 1H, J = 12.9 Hz), 3.46 (s, 3H), 3.41 (s, 
3H), 3.02 (m, 3H), 2.76 (m, 1H), 2.42 (s, 3H); 13C NMR (CDCl3, δ ppm) 171.1, 
170.8, 159.1, 149.9, 146.1, 143.8, 136.6, 130.8, 130.6, 129.6, 128.4, 127.2, 124.1, 
113.8, 58.4, 56.7, 56.2, 55.2, 55.1, 52.7, 52.6, 21.6; IR (thin film, cm-1) 3350, 3081, 
2985, 1744, 1732, 1537, 1381, 1177, 1143; HRMS (ES+) calculated for 
C29H35N4O11S2, [M+H]+ 679.1738, found [M+H]+ 679.1748. 
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(S)-Allyl 3-(((R)-3-methoxy-2-(4-methylphenylsulfonamido)-3-oxopropyl)(4-
methoxybenzyl)amino)-2-((4-nitrobenzyloxy)carbonylamino) propanoate (10). 10 was 
synthesised using a similar method to that used to synthesise 8, except the protected 
aziridine R-2a  was used (0.06 g, 0.25 mmol) and the protected DAP was 6c (0.22 g, 
0.5 mmol, 2 eq.). The crude product was purified by preparative TLC on silica gel 
(petroleum ether:ethyl acetate 4:1)  to yield 10 as a pale yellow oil (0.06 g, 38%). Rf: 
0.18 petroleum ether:ethyl acetate (1:1); [α]D20 = +21.31o (c 1.0 in CHCl3); 1H NMR 
(CDCl3, δ ppm) 8.21 (d, 2H, J = 8.3 Hz), 7.72 (d, 2H, J = 8.3 Hz), 7.57 (d, 2H, J = 8.0 
Hz), 7.27 (d, 2H, J = 8.0 Hz),  7.11 (d, 2H, J = 8.6 Hz), 6.77 (d, 2H, J = 8.6 Hz), 5.88 
(m, 2H), 5.79 (d, 1H, J = 8.2 Hz), 5.29 (m, 4H), 4.60 (pseudo t, 2H, J = 5.7 Hz), 4.43 
(dd, 1H, J = 8.2, 8.1 Hz), 4.14 (m, 1H), 3.77 (s, 3H), 3.70 (d, 1H, J = 12.9 Hz), 3.51 
(s, 3H), 3.33 (d, 1H, J = 13.0 Hz),  2.90-2.73 (m, 4H), 2.41 (s, 3H); 13C NMR (CDCl3, 
δ ppm) 170.9, 170.6, 159.0, 156.0, 147.5, 143.9, 143.5, 137.1, 131.2, 130.5, 129.5, 
129.2, 128.1, 127.1, 123.7, 119.3, 113.7, 66.6, 65.6, 57.6, 55.7, 55.4, 55.2, 54.3, 52.7, 
52.4, 21.5; IR (thin film, cm-1) 3401, 3083, 2971, 1749, 1737, 1671, 1386, 1249; 
HRMS (ES+) calculated for C33H39N4O11S, [M+H]+ 699.2331, found [M+H]+ 
699.2321. 
 
(S)-Allyl 3-(((S)-3-methoxy-2-(4-nitrophenylsulfonamido)-3-oxopropyl)(4-
methoxybenzyl)amino)-2-((4-nitrobenzyloxy)carbonylamino) propanoate (11). 11 was 
synthesised using a similar method to that used to synthesise 8, except the protected 
aziridine 2b was used (0.07 g, 0.25 mmol) and the protected DAP was 6c (0.22 g, 0.5 
mmol, 2 eq.). The crude product was purified by preparative TLC on silica gel in 
petroleum ether:ethyl acetate 4:1, to yield 11 as a pale yellow oil (0.05 g, 27%). Rf: 
0.22 petroleum ether:ethyl acetate (1:1); 1H NMR (CDCl3, δ ppm) 8.30 (d, 2H, J = 8.8 
Hz), 8.22 (d, 2H, J = 8.1 Hz), 8.00 (d, 2H, J = 8.8 Hz), 7.54 (d, 2H, J = 8.1 Hz), 7.10 
(d, 2H, J = 8.1 Hz), 6.81 (d, 2H, J = 8.1 Hz), 6.24 (s (br), 1H), 5.94 (m, 1H), 5.43-
5.24 (m, 5H), 4.60 (m, 2H, J = 5.6 Hz), 4.48-4.34 (m, 1H), 4.14 (m, 1H), 3.78 (s, 3H), 
3.76 (d, 1H, J = 13.2 Hz), 3.51 (s, 3H), 3.46 (d, 1H, J = 13.2 Hz), 2.98-2.85 (m, 2H), 
2.78-2.71 (m, 2H); 13C NMR (CDCl3, δ ppm) 170.6, 170.2, 159.2, 156.2, 149.9, 
147.8, 146.5, 143.4, 132.4, 131.1, 130.4, 128.3, 128.1, 123.9, 123.7, 119.5, 113.9, 
66.5, 65.9, 57.7, 56.6, 55.2, 54.9, 54.1, 52.8, 52.4; IR (thin film, cm-1) 3347, 3074, 
2991, 1749, 1733, 1677, 1547, 1386,  1192. 
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(S)-Allyl 3-(((R)-3-methoxy-2-(4-nitrophenylsulfonamido)-3-oxopropyl)(4-
methoxybenzyl)amino)-2-((4-nitrobenzyloxy)carbonylamino) propanoate (12). 12 was 
synthesised using a similar method to that used to synthesise 8, except the protected 
aziridine used was R-2b (0.07 g, 0.25 mmol). The crude product was purified by 
preparative TLC on silica gel in petroleum ether:ethyl acetate 4:1, to yield 12 as a pale 
yellow oil (0.06 g, 32%). Rf: 0.22 petroleum ether:ethyl acetate (1:1); [α]D20 = +67.20o 
(c 1.0 in CHCl3); 1H NMR (CDCl3, δ ppm) 8.30 (d, 2H, J = 8.8 Hz), 8.26 (d, 2H, J = 
8.6 Hz), 8.06 (d, 2H, J = 8.8 Hz), 7.57, (d, 2H, J = 8.9 Hz), 7.14 (d, 2H, J = 8.1 Hz), 
6.78 (d, 2H, J = 8.1 Hz), 6.51 (s (br), 1H), 5.86 (m, 1H), 5.34-5.22 (m, 5H), 4.60 (m, 
2H), 4.44 (pseudo t, 1H, J = 4.8 Hz), 4.30 (pseudo t, 1H, J = 4.9 Hz), 3.77 (d, 1H, J = 
13.2 Hz), 3.76 (s, 3H), 3.51 (s, 3H), 3.46 (d, 1H, J = 13.2 Hz), 2.94-2.88 (m, 2H), 
2.76, (d, 2H, J = 6.2 Hz); 13C NMR (CDCl3, δ ppm) 170.6, 170.2, 159.2, 156.2, 149.9, 
147.8, 146.5, 143.4, 132.4, 131.1, 130.4, 128.3, 128.1, 123.9, 123.7, 119.5, 113.9, 
66.5, 65.9, 57.7, 56.6, 55.2, 54.9, 54.1, 52.8, 52.4; IR (thin film, cm-1) 3359, 3079, 
2998, 1748, 1734, 1678, 1551, 1381,  1199. 
 
N-Triphenylmethyl-(S)-serine (13). To a suspension of S-serine (2.0 g, 18 mmol) in 
DCM (26 ml) under a nitrogen atmosphere, was added Me3SiCl (7.5 ml, 57 mmol) 
and the solution was stirred at reflux temperature for 20 min. The solution was 
allowed to cool to 0 oC and Et3N (8.3 ml, 57 mmol) in DCM (26 ml) was added 
dropwise over 10 min. to the solution which was then stirred for 45 min. The solution 
was cooled to 0 oC and anhydrous methanol (0.9 ml) was added dropwise. The 
solution was allowed to warm to room temperature, and Et3N (7.0 ml, 18 mmol) was 
added followed by triphenylmethyl chloride (4.6 g, 18 mmol), and the solution was 
stirred for 20 h at ambient temperature. An excess of Et3N (13 ml) and then methanol 
(94 ml) was added until the white solid present in the mixture was dissolved. The 
excess solvent was then removed in vacuo producing a white solid. The white solid 
was partitioned between ethyl acetate (67 ml) and citric acid (40.2 ml, 5% aq. w/v), 
which had been pre-cooled to 4 oC. The organic layer was washed with 2 M aqueous 
sodium hydroxide (2 x 20 ml) followed by water (3 x 15 ml). The aqueous layers 
were combined, washed with ethyl acetate (15 ml) and neutralised with glacial acetic 
acid (3-4 ml) at 0 oC. The precipitated product was extracted with ethyl acetate (6 x 
30 ml) and the organic layer was dried over anhydrous magnesium sulfate. The 
solvent was removed in vacuo to produce a white solid (3.1 g, 48%). M.pt. 109-110 
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oC; 1H NMR (CDCl3, δ ppm) 7.43 (d, 6H, J = 6.0 Hz), 7.32-7-29, 7.28 (m, 3H), 3.73-
3.71 (m, 1H), 3.50 (dd, 1H, J = 2.9, 2.9 Hz), 2.94-2.90 (m, 1H); 13C NMR (CDCl3, δ 
ppm) 174.9, 145.2, 129.3, 128.6, 126.2, 73.9, 67.5, 62.0; IR (KBr, cm-1) 3314, 3068, 
1732.  
The enantiomeric N-trityl-(R)-serine (R-13) was also prepared in a similar manner 
from (R)-serine. 
 
N-Triphenylmethyl-(S)-serine allyl ester (14). N-Triphenylmethyl-(S)-serine (0.30 g, 
0.87 mmol) was converted to its cesium salt by dissolving it in dry methanol (3.0 ml) 
containing Cs2CO3 (0.15 g, 0.45 mmol) under a nitrogen atmosphere. After removing 
the solvent in vacuo, the salt produced was re-dissolved in DMF (0.6 ml) and the 
resulting mixture was treated with allyl bromide (0.10 ml, 0.90 mmol). The solution 
was left stirring for a further 18 h at ambient temperature, after which the DMF was 
removed in vacuo. The mixture was then re-dissolved in ethyl acetate (3 ml) and 
washed with citric acid solution (1 x 10 ml, 5% aq. w/v). The aqueous layers were 
combined and extracted with ethyl acetate (2 x 10 ml), and the organic layers were 
combined and washed with water (12 x 10 ml). The organic layer was dried over 
anhydrous magnesium sulfate and the solvent was removed in vacuo producing a 
brown oil (0.30 g, 90%). Rf 0.73, hexane:ethyl acetate (2:1); 1H NMR (CDCl3, δ ppm) 
7.50 (dd, 6H, J = 8.4, 5.3 Hz), 7.25-7.22 (m, 9H), 5.70-5.67 (m, 1H), 5.18 (dd, 1H, J = 
1.5, 1.3 Hz), 5.13 (dd, 1H, J = 1.5, 1.5 Hz), 4.19-4-17 (m, 1H), 4.09-4.00 (m, 1H), 
3.72 (dd, 1H, J = 6.6, 6.4 Hz), 3.54 (dd, 2H, J = 4.2, 3.9 Hz); 13C NMR (CDCl3, δ 
ppm) 173.1, 145.1, 131.6, 128.7, 127.9, 126.6, 118.4, 71.0, 65.7, 64.9, 57.8; IR (thin 
film, cm-1) 3477, 3068, 2960, 1740, 1635. 
The enantiomeric R-14 was also prepared in a similar manner from N-trityl-(R)-
serine. 
 
2-(S)-Allyloxycarbonylamino-3-[(4-methoxy-benzyl)-(2-nitro-benzenesulfonyl)-
amino]-propionic acid allyl ester (15). To a solution of N-(p-methoxybenzyl)-2-
nitrobenzenesulfonamide10 (0.22 g, 0.70 mmol) in THF (3 ml) was added PPh3 (0.34 
g, 1.4 mmol), followed by the addition of N-triphenylmethyl-(S)-serine allyl ester 
(0.16 g, 1.4 mmol) and then diethyl azodicarboxylate (0.19 g, 1.2 mmol). The 
resulting mixture was allowed to stir at room temperature, under a nitrogen 
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atmosphere, for 10 h. The solvent was removed in vacuo giving an orange oil. 
Purification by flash column chromatography on silica gel in petroleum ether:ethyl 
acetate (4:1) gave 3-[(4-Methoxybenzyl)-(2-nitrobenzenesulfonyl)-amino]-2-(S)-
(tritylamino)-propanoic acid allyl ester as a white solid (0.23 g, 51%). Rf 0.36, 
petroleum ether:ethyl acetate (2:1); M.pt. 85-87 oC;  1H NMR (CDCl3, δ ppm) 8.01 
(dd, 1H, J = 4.6, 4.4 Hz), 7.89 (dd, 1H, J = 5.1, 5.1 Hz), 7.65 (m, 6H), 7.50-7.40 (m, 
2H), 7.24-7.16 (m, 9H), 7.00 (d, 2H, J = 8.7 Hz), 6.70 (d, 2H, J = 8.7 Hz), 5.64-5.60 
(m, 1H), 5.34 (m, 1H), 5.13 (dd, 2H, J = 10.2, 10.1 Hz), 4.46 (s, 2H), 4.34 (dd, 2H, J 
= 7.1, 6.9 Hz), 3.95-3.90 (m, 1H), 3.80 (s, 3H), 3.79-3.55 (m, 2H); 13C NMR (CDCl3, 
δ ppm) 169.2, 159.3, 145.5, 145.0, 135.2, 134.0 , 132.6, 131.1, 130.1, 129.6, 129.3, 
128.0, 126.5, 125.2, 124.2, 118.8, 114.0, 67.2, 64.2, 55.3, 55.0, 49.9, 47.4. IR (KBr, 
cm-1) 3347, 3163, 2901, 1721, 1605, 1561, 1130. MS (ES+) calculated for 
C39H37N3O7S, [M+H]+ 692.2, found [M+H]+ 692.1.  
3-[(4-Methoxybenzyl)-(2-nitrobenzenesulfonyl)-amino]-2-(S)-(tritylamino)propanoic 
acid allyl ester (0.10 g, 0.16 mmol) was treated with 50% TFA in CHCl3 (2.2 ml), 
under a nitrogen atmosphere, for 1 h. NaHCO3 (0.10 g, 2.2 mmol) was added with 
water (5 ml) and stirred for 5 min, then further NaHCO3 (0.10 g, 2.2 mmol) was 
added followed by allyl chloroformate (0.5 ml, 0.5 mmol). The mixture was stirred at 
room temperature for 12 h, diluted with ethyl acetate (20 ml) and washed with water 
(2 x 10 ml), dried over magnesium sulfate, and concentrated in vacuo producing a 
yellow oil. Purification by flash column chromatography on silica gel in petroleum 
ether:ethyl acetate (4:1) gave 15 as a yellow oil (0.050 g, 63%). Rf 0.57, petroleum 
ether:ethyl acetate (1:2); 1H NMR (CDCl3, δ ppm) 7.99 (d, 1H, J = 7.3 Hz), 7.69-7.60 
(m, 3H), 7.11 (d, 2H, J = 8.6 Hz), 6.78 (d, 2H, J = 8.6 Hz), 5.89-5.85 (m, 2H), 5.31-
5.29 (m, 4H), 4.68-4.41 (m, 5H), 4.21 (s, 2H), 3.77 (s, 3H), 3.72-3.49 (m, 2H); 13C 
NMR (CDCl3, δ ppm) 169.6, 159.5, 156.6, 147.7, 145.0, 135.1, 133.6, 132.4, 131.7, 
131.2, 129.8, 126.1, 124.3, 118.9, 118.0, 117.6, 68.6, 64.1, 55.2, 51.8, 50.4, 47.8; IR 
(thin film, cm-1) 3345, 3063, 2963, 1791, 1600, 1555, 1528, 1103; MS (ES+) 
calculated for C24H27N3O9S, [M+H]+ 534.1, found [M+H]+ 534.1. 
 
2-(S)-Allyloxycarbonylamino-3-(4-methoxy-benzylamino)-propionic acid allyl ester 
(16). Thiophenol (0.6 ml, 0.6 mmol) was dissolved in DMF (2 ml) and treated with 
K2CO3 (0.20 g, 1.6 mmol) in water (1 ml), which was then stirred at 0 oC for 10 min. 
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15 (0.10 g, 0.53 mmol) was dissolved in DMF (1 ml) and added to the thiophenol 
mixture and stirred overnight at room temperature under a nitrogen atmosphere. Ethyl 
acetate (10 ml) was added and the mixture washed with water (2 x 10 ml), dried over 
magnesium sulfate and concentrated in vacuo giving a yellow oil. Purification by 
flash column chromatography on silica gel in DCM:diethyl ether (2:1) removed the 
yellow fraction. Methanol:DCM (5:95) was then added to give 16 as a light brown oil 
(0.15 g, 80%). Rf 0.37, DCM:diethyl ether (2:1) (stain ninhydrin, yellow spot); 1H 
NMR (CDCl3, δ ppm) 7.20 (d, 2H, J = 8.4 Hz), 6.85 (d, 2H, J = 8.7 Hz), 5.95-5.82 
(m, 2H), 5.72 (d, 1H, J = 6.3 Hz), 5.34-5.23 (m, 4H), 4.64-4.56 (m, 4H), 4.44-4.41 
(m, 1H), 3.80 (s, 2H), 3.79 (s, 3H), 3.72 (dd, 2H, J = 4.5, 3.3 Hz). 13C NMR (CDCl3, 
δ ppm) 166.1, 159.7, 155.9, 146.7, 131.2, 128.9, 119.5, 67.9, 55.3, 52.8, 51.2, 48.7. IR 
(thin film, cm-1) 3311, 3030, 2876, 1720, 1666, 1489; MS (ES+) calculated for 
C18H24N2O5, [M+1] 649.2, found [M+1] 649.2. 
 
2-(S)-Allyloxycarbonylamino-3-{(4-methoxy-benzyl)-[2-(S)-methoxycarbonyl-2-
(toluene-4-sulfonylamino)-ethyl]-amino}-propionic acid allyl ester (17).  
Aziridine 2a (0.65 g, 0.28 mmol) and DAP 16 (0.10 g, 0.28 mmol) were dissolved in 
dry DCM (5 ml) and stirred at room temperature, under a nitrogen atmosphere, for 20 
min. Freshly distilled BF3.OEt2 (0.01 ml, 0.1 mmol) was then added and the mixture 
was stirred at 40 oC for 24 hr. The mixture was then diluted with DCM (10 ml) and 
washed with saturated aqueous NaHCO3 solution (10 ml) and water (10 ml), dried 
over magnesium sulfate, and then the solvent was removed in vacuo giving a brown 
residue. Purification by preparative TLC in petroleum ether:ethyl acetate (2:1) gave 
17 as a clear oil (48 mg, 30%). Rf 0.26, petroleum ether:ethyl aceatate (2:1); 1H NMR 
(CDCl3, δ ppm) 7.74 (d, 2H, J = 8.2 Hz), 7.30 (d, 2H, J = 8.0 Hz), 7.20 (d, 2H, J = 
5.3 Hz), 6.65 (d, 2H, J = 6.3 Hz), 5.99-5.82 (m, 2H), 5.73 (s, 1H, J = 17.4 Hz), 5.50 
(d, 1H, J = 12.9 Hz), 5.35-5.23 (m, 4H), 4.60 (dd, 4H, J = 5.6, 5.5 Hz), 4.44-4.36 (m, 
2H), 3.97 (dd, 2H, J = 4.2, 3.6 Hz), 3.88 (d, 2H, J = 3.6 Hz), 3.80 (s, 3H) 3.73 (d, 2H, 
J = 3.6 Hz), 2.96 (s, 3H), 2.42 (s, 3H); MS (ES+) calculated for C29H37N3O9S, 
[M+H]+ 604.3, found [M+H]+ 604.3. 
 
(2R)-Methyl 2-(((S)-3-methoxy-2-(4-nitrophenylsulfonamido)-3-oxopropyl)(4-
methoxybenzyl)amino)-3S-(4-methylphenylsulfonamido) propanoate (18). 
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18 was synthesised using a similar method to that used to synthesise 8, except the 
protected Dap 5a and aziridine 2a were used. The crude product was purified using 
preparatory TLC on silica gel (petroleum ether:ethyl acetate 4:1)  to yield 18 as a pale 
yellow oil (0.08 g, 47%). Rf: 0.29 petroleum ether:ethyl acetate (1:1); 1H NMR 
(CDCl3, δ ppm) 8.33 (d, 2H, J = 8.9 Hz), 8.00 (d, 2H, J = 8.7 Hz), 7.69 (d, 2H, J = 8.0 
Hz), 7.28 (d, 2H, J = 8.1 Hz), 7.08 (d, 2H, J = 8.4 Hz), 6.84 (d, 2H, J = 8.4 Hz), 3.98 
(t, 1H, J = 6.5 Hz), 3.81 (s, 3H), 3.73 (s, 3H), 3.65 (d, 1H, J = 13.0 Hz), 3.55 (d, 1H, J 
= 12.9 Hz), 3.50 (s, 3H), 3.46 (m, 1H), 3.23 (m, 1H), 3.09 (m, 2H), 3.00 (m, 1H), 2.42 
(s, 3H); 13C NMR (CDCl3, δ ppm) 170.9, 170.7, 159.3, 150.1, 145.5, 143.6, 136.6, 
130.4, 129.7, 128.4, 127.0, 124.2, 114.1, 62.7, 55.3, 55.3, 55.2, 54.5, 52.4, 52.1, 41.4, 
21.5; IR (thin film, cm-1) 3391, 3078, 2962, 1745, 1732, 1529, 1391, 1249, 1141. 
 
(2R)-Methyl 3-(((S)-1-allyloxy-3-(4-methylphenylsulfonamido)-1-oxopropan-2-yl)(4-
methoxybenzyl)amino)-2-(4-nitrophenylsulfonamido) propanoate (19) 
 
19 was synthesised using a similar method to that used to synthesise 18, except the 
protected Dap 5a and aziridine 2b were used. The crude product was purified using 
preparatory TLC on silica gel (petroleum ether:ethyl acetate 4:1)  to yield 19 as a pale 
yellow oil 0.07g, 39%). Rf: 0.24 petroleum ether:ethyl acetate (1:1); 1H NMR (CDCl3, 
δ ppm) 8.32 (d, 2H, J = 8.8 Hz), 8.00 (d, 2H, J = 8.8 Hz), 7.68 (d, 2H, J = 8.7 Hz), 
7.27 (d, 2H, J = 8.6 Hz), 7.11 (d, 2H, J = 8.7 Hz). 6.84 (d, 2H, J = 8.7 Hz), 5.66 (m, 
1H), 5.20 (m, 3H), 4.35 (d, 2H, J = 6.0 Hz), 3.97 (t, 1H), 3.81 (s, 3H), 3.72 (s, 3H), 
3.66 (d, 1H, J = 13.5 Hz), 3.57 (d, 1H, J = 13.5 Hz), 3.46 (m, 1H), 3.25 (m, 1H), 3.10-
2.98 (m, 3H), 2.41 (s, 3H); 13C NMR (CDCl3, δ ppm) 170.9, 170.0, 159.3, 150.1, 
145.5, 143.5, 136.7, 130.6, 130.5, 129.7, 128.5, 127.0, 124.3, 120.0, 114.1, 66.8, 62.8, 
55.5, 55.4, 55.3, 54.6, 52.1, 41.5, 21.5; IR (thin film, cm-1) 3376, 3065, 2963, 1751, 
1732, 1684, 1524, 1391,  1247. 
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(L)-Threonine methyl ester hydrochloride.8 A 250 ml 3-necked round-bottom flask 
was equipped with a condenser, a dropping funnel and a rubber septum. The 
condenser was fitted with a calcium chloride drying tube. The dropping funnel was 
charged with acetyl chloride (23.0 ml, 0.33 mol). The flask was filled with 75 mls of 
methanol and cooled to 0 oC in an ice bath under nitrogen. The acetyl chloride is 
added dropwise over 5 mins before L-threonine (13.58 g, 0.11 mol) was added before 
heating to reflux temperature. After 2 hours the solvent is removed in vacuo to yield a 
white fluffy solid (18.75 g, 97%) which was used without further purification.  1H 
NMR (CDCl3, δ ppm) 4.12 (d, 1H, J = 5.8 Hz), 3.87 (d, 1H, J = 5.8 Hz), 3.78 (dd, 1H, 
J = 5.3, 5.2 Hz), 3.67 (s, 3H), 1.21 (d, 3H, J = 6.0 Hz). 13C NMR (CDCl3, δ ppm) 
169.2, 60.9, 54.9, 52.1, 19.2. IR (KBr, cm-1)  3407, 2967, 1745. 
 
N-trityl-(L)-threonine methyl ester was synthesised using a similar method to that used 
to synthesise 14, except (L)-threonine methyl ester hydrochloride (0.54 g, 3.2 mmol) 
was used, to yield a white solid (0.98 g, 82%).8 Rf: 0.50 petroleum ether:ethyl acetate 
(2:1). 1H NMR (CDCl3, δ ppm) 7.49 (m, 6H), 7.31-7.14 (m, 9H), 3.78 (m, 1H), 3.38 
(d, 1H J = 3.5 Hz), 3.15 (s, 3H), 1.22 (d, 3H J = 6.3 Hz). 13C NMR (CDCl3, δ ppm) 
173.7, 145.4, 128.9, 127.9, 126.6, 69.7, 62.5, 53.4, 51.7, 18.9. IR (KBr, cm-1)  3481, 
3055, 2978, 1732, 1592. 
 
N-Triphenylmethyl-(L)-threonine. N-Triphenylmethyl-(L)-threonine was synthesised 
using a similar method to that used to synthesise N-triphenylmethyl-(S)-serine (13), 
except L-threonine (1.13 g, 9.5 mmol) was used to yield a white solid (2.02 g, 59%). 
1H NMR (CDCl3, δ ppm) 7.40 (d, 6H, J = 6.0 Hz), 7.28-7.15 (m, 9H), 3.91 (m, 1H), 
3.52 (dd, 1H, J = 5.9, 5.8 Hz), 1.19 (d, 3H, J = 5.6 Hz); 13C NMR (CDCl3, δ ppm) 
174.6, 145.2, 128.6, 127.7, 126.6, 70.6, 60.5, 54.8, 18.3; IR (KBr, cm-1) 3341, 3082, 
2977, 1737. 
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N-Triphenylmethyl-(L)-threonine allyl ester. N-Triphenylmethyl-(L)-threonine allyl 
ester was synthesised using a similar method to that used to synthesise N-trityl-(L)-
serine methyl ester, except N-triphenylmethyl-(L)-threonine (0.31 g, 0.87 mmol) was 
used to yield a brown oil (0.31 g, 90%). Rf: 0.60 petroleum ether:ethyl acetate (2:1); 
1H NMR (CDCl3, δ ppm) 7.49 (m, 6H), 7.28-7.12 (m, 9H), 5.63 (m, 1H), 5.16 (m, 
2H), 4.06 (m, 1H), 3.82 (m, 2H), 3.40 (d, 1H J = 7.3 Hz), 1.22 (d, 3H J = 6.1 Hz); 13C 
NMR (CDCl3, δ ppm) 173.0, 145.5, 131.6, 129.0, 127.9, 126.7, 118.8, 70.8, 69.8, 
62.5, 53.5, 19.0; IR (thin film, cm-1) 3446, 3058, 2931, 1732, 1674. 
 
(2S,3R)-Methyl-1-(trityl)-aziridine-2-carboxylic acid methyl ester (20a). 20a was 
synthesised using a similar method to that used to synthesise 1a, except N-trityl-(L)-
threonine methyl ester (2.06 g, 5.5 mmol) was used, to yield a cloudy oil (1.79 g, 
91%). Rf: 0.82 petroleum ether:ethyl acetate (2:1); 1H NMR (CDCl3, δ ppm) 7.53 (m, 
6H), 7.28-7.13 (m, 9H), 3.67 (s, 3H), 1.90 (dd, 1H, J = 3.8, 3.7 Hz), 1.66 (m, 1H), 
1.36 (d, 3H, J = 6.2 Hz); 13C NMR (CDCl3, δ ppm) 170.8, 144.2, 129.5, 127.7, 127.0, 
75.1, 51.9, 36.1, 35.0, 13.4; IR (thin film, cm-1) 3069, 2947, 1739. 
 
(2S,3R)-Methyl-1-trityl-aziridine-2-carboxylic acid allyl ester (20b). 20b was 
synthesised using a similar method to that used to synthesise 1b, except N-
triphenylmethyl-(L)-threonine allyl ester (2.07 g, 5.16 mmol) was used to yield 20b as 
a yellow oil (1.72 g, 87%). Rf: 0.90 petroleum ether:ethyl acetate (2:1); 1H NMR 
(CDCl3, δ ppm) 7.45 (m, 6H), 7.31-7.19 (m, 9H), 5.88 (m, 1H), 5.24 (m, 2H), 4.59 
(m, 2H), 1.84 (d, 1H J = 6.5 Hz), 1.55 (m, 1H), 1.27 (d, 3H J = 5.5 Hz); 13C NMR 
(CDCl3) δ ppm; 170.0, 143.9, 132.2, 129.4, 128.3, 126.6, 118.5, 82.0, 65.4, 36.0, 
35.0, 13.4; IR (thin film, cm-1) 3080, 2975, 1742, 1641. 
 
(2S,3R)-Methyl-1-(p-tosyl)-aziridine-2-carboxylic acid methyl ester (21a). 21a was 
synthesised using a similar method to that used to synthesise 2a, except 20a (2.07 g, 
5.8 mmol) was used to yield a clear oil (1.26 g, 81%). Rf: 0.47 petroleum ether:ethyl 
acetate (2:1); 1H NMR (CDCl3, δ ppm) 7.85 (d, 2H, J = 8.4 Hz), 7.35 (d, 2H, J = 8.3 
Hz), 3.73 (s, 3H), 3.39 (d, 1H, J = 7.5 Hz), 3.10 (m, 1H), 2.44 (s, 3H), 1.32 (d, 3H, J = 
5.6 Hz); 13C NMR (CDCl3, δ ppm) 166.2, 145.0, 136.6, 129.8, 128.0, 53.0, 41.4, 40.1, 
21.6, 12.4;  IR (thin film, cm-1) 3072, 2979, 1741, 1214 .  
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(2S,3R)-Methyl-1-(p-nosyl)-aziridine-2-carboxylic acid methyl ester (21b). 21b was 
synthesised using a similar method to that used to synthesise 2b, except 20a (2.07 g, 
5.8 mmol) was used to yield a yellow oil (1.39 g, 80%). Rf: 0.51 petroleum ether:ethyl 
acetate (2:1); 1H NMR (CDCl3, δ ppm) 8.35 (d, 2H, J = 8.8 Hz), 8.14 (d, 2H, J = 8.8 
Hz), 3.68 (s, 3H), 3.44 (d, 1H, J = 7.5 Hz), 3.18 (m, 1H), 1.21 (d, 3H, J = 5.7 Hz); 13C 
NMR (CDCl3, δ ppm) 165.6, 150.8, 145.4, 129.2, 124.4, 52.8, 42.2, 40.7, 12.4; IR 
(thin film, cm-1) 3080, 2967, 1747, 1540, 1379, 1276. 
 
(2S,3R)-Methyl-1-(p-nitrobenzyloxycarbony)-aziridine-2-carboxylic acid methyl ester 
(21c). 21c was synthesised using a similar method to that used to synthesise 2c, 
except 20a (2.07 g, 5.8 mmol) was used to yield a yellow oil (1.33 g, 78%). Rf: 0.45 
petroleum ether:ethyl acetate (2:1); 1H NMR (CDCl3, δ ppm) 8.08 (d, 2H, J = 8.8 Hz), 
7.44 (d, 2H, J = 8.8 Hz), 5.12 (d, 2H, J = 3.1 Hz), 3.67 (s, 3H), 3.18 (d, 1H, J = 6.7 
Hz), 2.78 (m, 1H), 1.27 (d, 3H, J = 5.6 Hz); 13C NMR (CDCl3, δ ppm) 171.4, 161.2, 
147.6, 143.9, 129.2, 123.4, 66.8, 53.6, 39.8, 39.0, 12.6; IR (thin film, cm-1) 3065, 
2981, 1744, 1680, 1528, 1397, 1212.  
 
(2S,3R)-Methyl-1-(p-tosyl)-aziridine-2-carboxylic acid allyl ester (22a). 22a was 
synthesised using a similar method to that used to synthesise 3a, except 20b (2.07 g, 
5.4 mmol) was used to yield a clear oil (1.34 g, 84%). Rf: 0.47 petroleum ether:ethyl 
acetate (2:1); 1H NMR (CDCl3, δ ppm)  7.85 (d, 2H, J = 8.8 Hz), 7.35 (d, 2H, J = 8.8 
Hz), 5.88 (m, 1H), 5.22 (m, 2H), 4.65 (d, 2H, J = 6.0 Hz), 3.39 (d, 1H, J = 6.6 Hz), 
3.10 (m, 1H), 2.44 (s, 3H), 1.32 (d, 3H, J = 5.8 Hz); 13C NMR (CDCl3, δ ppm) 166.2, 
145.0, 136.6, 131.1, 129.8, 128.0, 119.0, 66.5, 41.4, 40.1, 21.6, 12.4; IR (thin film, 
cm-1) 3090, 2992, 1740, 1621, 1220.  
 
(2S,3R)-Methyl-1-(p-nosyl)-aziridine-2-carboxylic acid allyl ester (22b). 22b was 
synthesised using a similar method to that used to synthesise 3b, except 20b (2.07 g, 
5.4 mmol) was used to yield a yellow oil (1.35g, 77%). Rf: 0.54 petroleum ether:ethyl 
acetate (2:1); 1H NMR (CDCl3, δ ppm) 8.35 (d, 2H, J = 9.0 Hz), 8.14 (d, 2H, J = 8.9 
Hz), 5.86 (m 1H), 5.26 (m, 2H), 4.57 (d, 2H, J = 5.8 Hz), 3.48 (d, 1H, J = 7.5 Hz), 
3.20 (m, 1H), 1.29 (d, 3H J = 5.7 Hz); 13C NMR (CDCl3, δ ppm) 164.8, 150.8, 143.5, 
130.9, 129.2, 124.4, 119.5, 66.5, 42.0, 40.7, 12.3; IR (thin film, cm-1) 3077, 2954, 
1742, 1538, 1371, 1242. 
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(2S,3R)-Methyl-1-(p-nitrobenzyloxycarbony)-aziridine-2-carboxylic acid allyl ester 
(22c). 22c was synthesised using a similar method to that used to synthesise 3c, 
except 20b (2.07 g, 5.4 mmol) was used to yield a yellow oil (1.29 g, 75%). Rf: 0.42 
petroleum ether:ethyl acetate (2:1); 1H NMR (CDCl3, δ ppm) 8.25 (d, 2H, J = 8.8 Hz), 
7.55 (d, 2H, J = 8.8 Hz), 5.90 (m, 1H), 5.38-5.19 (m, 4H), 4.70 (d, 2H, J = 5.8 Hz), 
3.23 (d, 1H, J = 6.7 Hz), 2.88 (m, 1H), 1.39 (d, 3H, J = 5.6 Hz); 13C NMR (CDCl3, δ 
ppm) 166.6, 161.1, 147.8, 142.4, 131.3, 128.5, 123.8, 119.2, 66.9, 66.2, 39.9, 39.1, 
12.7; IR (thin film, cm-1) 3068, 2982, 1741, 1681, 1640, 1209. 
 
 
DAPs 23a, 24a, 23b, 24b, 25a-c and 26 were prepared by ring-opening of 3-methyl 
aziridines with p-methoxybenzylamine using the general procedure used to prepare 
DAPs 4a-c and 6c. 
(2S,3R)-Methyl 3-(4-methoxybenzylamino)-2-(4-methylphenylsulfonamido) butanoate 
(23a). Cloudy oil (0.08 g, 41%); Rf: 0.18 petroleum ether:ethyl acetate (1:1); [α]D20 = 
+16.55o (c 1.0 in CHCl3); 1H NMR (CDCl3, δ ppm) 7.71 (d, 2H, J = 8.1 Hz), 7.28 (d, 
2H, J = 8.0 Hz), 7.13 (d, 2H, J = 8.4 Hz), 6.82 (d, 2H, J = 8.4 Hz), 3.81 (d, 1H, J = 
3.6 Hz), 3.80 (s, 3H), 3.68 (d, 1H, J = 12.8 Hz), 3.55 (d, 1H, J = 12.8 Hz), 3.45 (s, 
3H), 3.09 (m, 1H), 2.41 (s, 3H), 1.13 (d, 3H, J = 6.2 Hz); 13C NMR (CDCl3, δ ppm) 
171.1, 158.7, 143.5, 136.7, 131.8, 129.5, 129.3, 127.2, 113.7, 60.4, 55.2, 53.9, 52.3, 
50.3, 21.5, 17.6; IR (thin film, cm-1) 3411, 3077, 2977, 1733, 1213, 1126; HRMS 
(ES+) calculated for C20H27N2O5S, [M+H]+ 407.1635, found [M+H]+ 407.1628. 
 
(2S,3R)-Methyl 3-(4-methoxybenzylamino)-2-(4-nitrophenylsulfonamido) butanoate 
(23b). Pale yellow oil (0.09 g, 42%); Rf: 0.45 petroleum ether:ethyl acetate (1:1); 
[α]D20 = +7.10o (c 1.0 in CHCl3); 1H NMR (CDCl3, δ ppm) 8.32 (d, 2H, J = 8.7 Hz), 
8.03 (d, 2H, J = 8.7 Hz), 7.13 (d, 2H, J = 8.4 Hz), 6.83 (d, 2H, J = 8.5 Hz), 3.88 (d, 
1H, J = 3.2 Hz), 3.78 (s, 3H), 3.65 (d, 2H, J = 12.6 Hz), 3.49 (d, 1H, J = 12.7 Hz), 
3.47 (s, 3H), 3.18 (m, 1H), 1.17 (d, 2H, J = 5.6 Hz); 13C NMR (CDCl3, δ ppm) 170.8, 
158.9, 149.9, 145.9, 131.0, 129.4, 128.4, 124.6, 113.8, 60.2, 55.3, 53.8, 52.6, 50.6, 
18.0; IR (thin film, cm-1) 3352, 3066, 2967, 1741, 1521, 1386, 1191; HRMS (ES+) 
calculated for C19H24N3O7S, [M+H]+ 438.1329, found [M+H]+ 438.1330. 
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(2R,3S)-Methyl 2-(4-methoxybenzylamino)-3-(4-methylphenylsulfonamido) butanoate 
(24a). Rf: 0.29 petroleum ether:ethyl acetate (1:1); 1H NMR (CDCl3, δ ppm) 7.64 (d, 
2H, J = 8.4 Hz), 7.20 (d, 2H, J = 8.4 Hz), 7.10 (d, 2H, J = 8.6 Hz), 6.78 (d, 2H, J = 
8.6 Hz), 3.73 (s, 3H), 3.65-3.50 (dd, 2H, J = 12.6, 12.6 Hz), 3.56 (s, 3H), 3.50 (d, 1H, 
J = 12.6 Hz)3.43 (m, 1H), 3.01 (d, 1H, J = 5.1 Hz), 2.33 (s, 3H), 1.02 (d, 3H, J = 6.5 
Hz). 13C NMR (CDCl3, δ ppm) 172.8, 158.9, 143.3, 137.5, 130.7, 129.6, 129.6, 127.2, 
113.8, 64.2, 55.3, 52.4, 52.0, 51.5, 21.5, 17.6; IR (thin film, cm-1) 3365, 3089, 2982, 
1738, 1194, 1133. 
 
(2S,3R)-Allyl 3-(4-methoxybenzylamino)-2-(4-methylphenylsulfonamido) butanoate 
(25a). Pale yellow oil (0.09 g, 42%); Rf: 0.2 petroleum ether:ethyl acetate (1:1); [α]D20 
= +21.83o (c 1.0 in CHCl3); 1H NMR (CDCl3, δ ppm) 7.72 (d, 2H, J = 8.3 Hz), 7.27 
(d, 2H, J = 8.3 Hz), 7.15 (d, 2H, J = 8.4 Hz), 6.83 (d, 2H, J = 8.4 Hz), 5.66 (m, 1H), 
5.16 (m, 2H), 4.38-4.25 (dd, 2H, J = 6.0, 6.0 Hz), 3.82 (d, 1H, J = 3.6 Hz), 3.78 (s, 
3H), 3.71 (d, 1H, J = 13.2 Hz), 3.54 (d, 1H, J = 13.2 Hz), 3.12 (m, 1H), 2.40 (s, 3H), 
1.15 (d, 3H, J = 6.5 Hz); 13C NMR (CDCl3, δ ppm) 170.3, 158.7, 143.5, 136.7, 131.7, 
131.1, 129.6, 129.3, 127.2, 119.0, 113.7, 66.1, 60.1, 55.2, 54.0, 50.3, 21.5, 17.5; IR 
(thin film, cm-1) 3346, 3081, 2962, 1744, 1612, 1201, 1152; HRMS (ES+) calculated 
for C22H29N2O5S, [M+H]+ 433.1792, found [M+H]+ 433.1796. 
 
(2S,3R)-Allyl 3-(4-methoxybenzylamino)-2-(4-nitrophenylsulfonamido) butanoate 
(25b). Pale yellow oil (0.1 g, 43%); Rf: 0.41 petroleum ether:ethyl acetate (1:1); [α]D20 
= +12.37o (c 1.0 in CHCl3); 1H NMR (CDCl3, δ ppm) 8.31 (d, 2H, J = 8.8 Hz), 8.01 
(d, 2H, J = 8.8 Hz), 7.12 (d, 2H, J = 8.5 Hz), 6.84 (d, 2H, J = 8.5 Hz), 5.63 (m, 1H), 
5.18 (m, 2H) 4.42 (dd, 1H, J = 12.8, 6.1 Hz),  4.30 (dd, 1H, J = 12.7, 6.1 Hz), 3.88 (d, 
1H, J = 4.6 Hz), 3.78 (s, 3H), 3.68 (d, 1H, J = 12.8 Hz), 3.51 (d, 1H, J = 12.8 Hz), 
3.21 (m, 1H), 1.19 (d, 3H, J = 6.3 Hz); 13C NMR (CDCl3, δ ppm) 170.1, 158.8, 149.9, 
145.9, 131.6, 130.0, 129.2, 128.4, 124.6, 119.5, 113.8, 66.4, 60.3, 55.2, 53.9, 50.8, 
18.2 ; IR (thin film, cm-1) 3397, 3069, 2981, 1738, 1612, 1557, 1379, 1176; HRMS 
(ES+) calculated for C21H26N3O7S, [M+H]+ 464.1486, found [M+H]+ 464.1504. 
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(2S,3R)-Allyl 3-(4-methoxybenzylamino)-2-((4-nitrobenzyloxy)carbonylamino) 
butanoate (25c). Pale yellow oil (0.09 g, 39%); Rf: 0.50 petroleum ether:ethyl acetate 
(1:1); [α]D20 = +29.62o (c 1.0 in CHCl3); 1H NMR (CDCl3, δ ppm) 8.19 (d, 2H J = 8.8 
Hz), 7.51 (d, 2H J = 8.8 Hz), 7.17 (d, 2H J = 8.9 Hz), 6.85 (d, 2H J = 8.8 Hz), 6.08 (s 
(br), 1H), 5.90 (m, 1H), 5.36-5.25 (m, 2H), 4.80 (s, 2H), 4.64 (d, 2H, J = 6.0 Hz), 4.27 
(pseudo t, 2H, J = 4.3 Hz), 3.79 (s, 3H), 3.24 (d, 1H J = 7.2 Hz), 2.78 (m, 1H), 1.29 
(d, 3H J = 5.6 Hz); 13C NMR (CDCl3, δ ppm) 167.8, 163.1, 159.0, 148.5, 147.5, 
131.4, 129.8, 129.2, 126.9, 123.6, 119.1, 114.0, 66.2, 63.8, 55.3, 44.4, 40.5, 39.4, 
13.0; IR (thin film, cm-1) 3380, 3071, 2980, 1742, 1666, 1206; HRMS: (ES+) 
calculated for C23H28N3O7, calculated [M+H]+  458.1943, found [M+H]+ 458.1922. 
 
(2R,3S)-Allyl 2-(4-methoxybenzylamino)-3-(4-nitrophenylsulfonamido) butanoate 
(26b). Rf: 0.52 petroleum ether:ethyl acetate (1:1). 1H NMR (CDCl3, δ ppm) 8.28 (d, 
2H, J = 8.8 Hz), 7.96 (d, 2H, J = 8.7 Hz), 7.07 (d, 2H, J = 8.4 Hz), 6.80 (d, 2H, J = 
8.4 Hz), 5.63 (m, 1H), 5.18 (m, 2H), 4.26 (dd, 2H, J = 6.2, 6.1 Hz), 3.80 (s, 3H), 3.72 
(d, 1H, J = 12.9 Hz), 3.58 (d, 1H, J = 12.9 Hz), 3.28 (m, 1H), 2.98 (d, 1H, J = 7.4 Hz), 
1.07 (d, 2H, J = 5.8 Hz). 13C NMR (CDCl3, δ ppm) 172.8, 158.8, 149.9, 147.6, 131.5, 
130.9, 129.0, 128.5, 124.1, 119.2, 113.8, 66.5, 63.8, 55.2, 52.9, 51.1, 18.1. IR (thin 
film, cm-1) 3368, 3068, 2979, 1739, 1622, 1552, 1378, 1165. 
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Supporting Information 
 
All isolated products were purified using column chromatography with silica gel (Aldrich, 
70-230 mesh, 60 Å) in the indicated solvent systems. Melting points were determined with 
Stuart scientific SMP1 & Mettler FP62 melting point apparatus. Analytical thin layer 
chromatography (TLC) was performed on pre-coated plates (Merck Kieselgel 60 F254) and 
visualised with UV light (254 nm), iodine vapour or aqueous potassium permanganate 
solution. Infrared spectra were recorded as KBr disks or a thin film between sodium chloride 
plates, on Avatar 320 and Nicolet impact 410 FT-IR spectrophotometers, run on EZ Omnic 
E.S.P 5.2a and 3.1a software packages, respectively. Polarimetry was carried out using an 
Optical Activity AA-55 series polarimeter at ambient temperature with a 2 dm, 1 ml cell. 1H 
NMR and 13C NMR spectra were measured on a JOEL JNM-LA300 FT-NMR or a Bruker 
Avance III 500 MHz FT-NMR with TopSpin 2.16 Software and 5mm PATXI 1H/13-C/15N 
Z-GRD probe, in CDCl3 as solvent. Chemical shift values are reported relative to 
tetramethylsilane. Mass Spectrometry was carried out at the Centre for Synthesis and 
Chemical Biology in University College Dublin using Quattro microTM LC-MS/MS and 
Liquid chromatography time-of-flight (LCT) mass spectrometers. Exact Mass Spectrometry 
analyses were carried out at the Department of Chemistry, NUI Maynooth, Co. Kildare, 
Ireland. 
 
N-Trityl-(S)-serine methyl ester. To a suspension of (S)-serine methyl ester hydrochloride 
(0.50 g, 3.2 mmol) in DCM (7 ml) at 0 oC, under a nitrogen atmosphere, was added dropwise 
triethylamine (1.0 ml, 7.1 mmol), followed by a solution of triphenylmethyl chloride (0.91 g, 
3.2 mmol) in DCM (2 ml). After stirring at 0 oC for 12 h the white precipitate was filtered 
and the filtrate was concentrated in vacuo to yield a white solid which was dissolved in ethyl 
acetate (10 ml), washed with 1 M aqueous NaHCO3 solution (10 ml), 10% aqueous citric acid 
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solution (10 ml) and water (10 ml). The organic layer was dried over anhydrous magnesium 
sulfate and concentrated in vacuo giving a white solid. Purification by flash column 
chromatography on silica gel in petroleum ether:ethyl acetate (4:1), gave N-trityl-(S)-serine 
methyl ester as a white solid (0.99 g, 86%). Rf: 0.42, petroleum ether:ethyl acetate (2:1); 
M.pt. 98-100 oC; [α]D20 = +3.65o  (c 1.0 in CHCl3) (Lit. Value [α]D20 = +3.60o (c 1 in 
CHCl3))1; 1H NMR (CDCl3, δ ppm) 7.47 (m, 6H), 7.21 (m, 9H), 3.73 (dd, 1H, J = 4.2 and 4.1 
Hz), 3.56 (m, 2H), 3.26 (s, 3H); 13C NMR (CDCl3, δ ppm) 173.9, 145.5, 128.6, 127.8, 126.5, 
70.8, 64.8, 57.7, 51.8; IR (KBr, cm-1) 3354, 3060, 2947, 1731.  
The enantiomeric N-trityl-(R)-serine methyl ester was also prepared in a similar manner from 
(R)-serine methyl ester hydrochloride. 
 
1-Trityl-aziridine-2S-carboxylic acid methyl ester (1a). Triethylamine (1.68 ml, 12.1 mmol) 
was added dropwise over 10 min to a stirred solution of N-trityl-(S)-serine methyl ester (2.0 
g, 5.5 mmol) in THF (50 ml) at 0 oC, followed by the dropwise addition of methanesulfonyl 
chloride (0.47 ml, 60.0 mmol) and the solution was stirred at 0 oC for 30 mins giving the 
mesylate intermediate and was subsequently heated at reflux temperature for 48 h. After 
completion of the reaction, solvent was removed under reduced pressure. The resulting 
residue was dissolved in EtOAc (60 ml) and washed with 10% aqueous citric acid solution (3 
x 20 ml), H2O (2 x 20 ml), saturated aqueous Na2CO3 solution (3 x 20 ml), H2O (2 x 20 ml) 
and brine (20 ml). The organic layer was dried over anhydrous magnesium sulfate, filtered 
and concentrated in vacuo. Purification by flash column chromatography on silica gel in 
petroleum ether:ethyl acetate (4:1), gave 1a as a cloudy oil (1.8 g, 95%). Rf: 0.84 petroleum 
ether:ethyl acetate (2:1); [α]D20 = -94o (c 1.0 in CHCl3) (Lit. Value [α]D20 = -94.22o (c 1 in 
CHCl3))2; 1H NMR (CDCl3, δ ppm) 7.47 (dd, J = 7.1, 7.2 Hz), 7.34-7.30 (m, 6H), 7.28-7.23 
(m, 3H), 3.66 (s, 3H), 1.88 (dd, 2H, J = 4.1, 3.9 Hz), 1.42 (dd, 1H, J = 4.1, 4.1 Hz); 13C NMR 
(CDCl3, δ ppm) 170.5, 146.7, 129.3, 127.9, 126.9, 74.5, 65.7, 31.7, 28.7; IR (thin film, cm-1) 
3058, 2925, 1744. 
The enantiomeric R-1a was also prepared in a similar manner from N-trityl-(R)-serine methyl 
ester. 
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1-(p-Tosyl)-aziridine-2S-carboxylic acid methyl ester (2a). Trifluoroacetic acid (10 ml) was 
added dropwise over 10 min to a solution of 1a (2.0 g, 5.8 mmol) in dichloromethane (10 ml) 
and methanol (10 ml) at 0 oC and stirred for 30 min at 0 oC. Volatiles were removed by 
azeotropic removal with Et2O (3 x 10 ml). The residue was partitioned between Et2O (50 ml) 
and H2O (50 ml) and the ether layer was extracted with water (3 x10 ml). The combined 
aqueous layers were basified to pH 9 with solid NaHCO3 at 0 oC. Ethyl acetate (100 ml) was 
added to the aqueous solution followed by p-toluenesulfonyl chloride (1.11 g, 5.8 mmol) at 0 
oC. The resulting immiscible layers were allowed to warm to room temperature and stirred 
vigorously for 24 h. After completion of the reaction, the two layers were separated and the 
aqueous layer was extracted with EtOAc (3 x 20 ml). The combined organic layers were 
washed with brine (3 x 50 ml), dried over anhydrous magnesium sulfate, filtered and 
concentrated in vacuo. The crude product was purified by flash column chromatography on 
silica gel in petroleum ether:ethyl acetate (4:1)  to yield 2a as a clear oil (1.36 g, 92%). [α]D20 
= -54.81o (c 1.0 in CHCl3) (Lit. Value [α]D = -55.2o (c 1.17 in CHCl3))3; 1H NMR (CDCl3, δ 
ppm) 7.78 (d, 2H, J = 8.4 Hz), 7.30 (d, 2H, J = 8.4 Hz), 3.73 (s, 3H), 3.33 (m, 1H), 2.76 (d, 
1H, J = 7.2 Hz), 2.59 (d, 1H, J = 4.2 Hz), 2.44 (s, 3H); 13C NMR (CDCl3, δ ppm) 167.3, 
145.4, 133.7, 129.8, 128.1, 52.8, 35.6, 31.9, 21.8; IR (thin film, cm-1) 3079, 2983, 1741, 
1220. 
The enantiomeric R-2a was also prepared in a similar manner from R-1a. 
   
1-(p-Nosyl)-aziridine-2S-carboxylic acid methyl ester (2b). 2b was synthesised using a 
similar method to that used to synthesise 2a, except 4-nitrobenzylsulfonyl chloride was used. 
The crude product was purified by flash column chromatography on silica gel in petroleum 
ether:ethyl acetate (4:1) to yield 2b as a yellow oil (1.29 g, 85%). Rf: 0.48 petroleum 
ether:ethyl acetate (2:1); [α]D20 = -61.77o (c 1.0 in CHCl3); 1H NMR (CDCl3, δ ppm) 8.36 (d, 
2H, J = 9.0 Hz), 8.13 (d, 2H, J = 9.0 Hz), 3.69 (s, 3H), 3.38 (m, 1H), 2.83 (d, 1H J = 7.1 Hz), 
2.60 (d, 1H J = 4.2 Hz); 13C NMR (CDCl3, δ ppm) 166.6, 154.1, 142.9, 129.5, 124.5, 53.1, 
36.1, 32.5;  IR (thin film, cm-1) 3084, 2918, 1750, 1546 , 1369, 1312, 1297. 
The enantiomeric R-2b was also prepared in a similar manner from R-1a. 
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1-(p-Nitrobenzyloxycarbonyl)-aziridine-2S-carboxylic acid methyl ester (2c). 2c was 
synthesised using a similar method to that used to synthesise 2a, except 4-nitrobenzyl 
chloroformate was used. The crude product was purified using flash column chromatography 
on silica gel in petroleum ether:ethyl acetate (4:1) to yield 2c as a yellow oil (1.38 g, 82%). 
Rf: 0.48 petroleum ether:ethyl acetate (2:1); [α]D20 = -30.26o (c 1.0 in CHCl3) (Lit. Value [α]D 
= -30.26o (c 1 in CHCl3))2; 1H NMR (CDCl3, δ ppm) 8.15 (d, 2H, J = 8.8 Hz), 7.46 (d, 2H, J 
= 8.6 Hz), 5.19 (d, 2H, J = 5.2 Hz), 3.67 (s, 3H),  3.09 (dd, 1H, J = 4.2 Hz and J = 4.2 Hz), 
2.57 (dd, 1H, , J = 1.3, 1.3 Hz), 2.45 (dd, 1H, , J = 1.2, 1.2 Hz); 13C NMR (CDCl3, δ ppm) 
169.0, 160.2, 147.9, 142.6, 128.5, 123.7, 66.9, 53.1, 35.0, 31.4; IR (thin film, cm-1) 3071, 
2936, 1742, 1690, 1516, 1351, 1303, 1281. 
The enantiomeric R-2c was also prepared in a similar manner from R-1a. 
 
1-Trityl-aziridine-2S-carboxylic acid allyl ester (1b). 1b was synthesised using a similar 
method to that used to synthesise 1a, except 13 (2.0 g, 5.16 mmol) was used instead of N-
trityl-(S)-serine methyl ester. Purification by flash column chromatography on silica gel in 
petroleum ether:ethyl acetate (4:1), gave 1b as a white solid (1.75 g, 92%). Rf: 0.85 
petroleum ether:ethyl acetate (2:1); [α]D20 = -97.12o (c 1.0 in CHCl3) (Lit. Value [α]D20 (c 1 in 
CHCl3) = -97.01o)2; 1H NMR (CDCl3, δ ppm) 7.46 (dd, J = 7.2, 7.1 Hz), 7.31-7.27 (m, 6H), 
7.26-7.23 (m, 3H), 5.84-5.72 (m, 1H), 5.37 (dd, 1H, J = 7.1, 6.3 Hz). 5.24-5.19 (m, 1H), 
4.70-4.66 (m, 2H), 1.90 (dd, 2H, J = 4.1, 3.9 Hz), 1.42 (dd, 1H, J = 4.1, 4.1 Hz); 13C NMR 
(CDCl3, δ ppm) 171.0, 145.8, 129.6, 128.7, 126.8, 131.7, 118.5, 74.3, 65.7, 31.7, 28.7; IR 
(thin film, cm-1) 3091, 2966, 1749, 1672. 
The enantiomeric R-1b was also prepared in a similar manner from R-7. 
 
1-(p-Tosyl)-aziridine-2S-carboxylic acid allyl ester (3a). 3a was synthesised using a similar 
method to that used to synthesise 2a, except 1b and 4-toluenesulfonyl chloride (1.04 g, 5.4 
mmol) were used. The crude product was purified using flash column chromatography on 
silica gel in petroleum ether:ethyl acetate (4:1)  to yield 3a as a clear oil (1.28 g, 83%). Rf: 
0.5 petroleum ether:ethyl acetate (2:1); [α]D20 = -58.37o (c 1.0 in CHCl3); 1H NMR (CDCl3, δ 
ppm) 7.86 (d, 2H, J = 8.4 Hz), 7.37 (d, 2H, J = 8.4 Hz), 5.93-5.84 (m, 1H), 5.26-5.14 (m, 
2H), 4.60 (d, 2H, J = 7.2 and 6.2 Hz), 3.36 (m, 1H), 2.76 (d, 1H, J = 7.2 Hz), 2.58 (d, 1H, J 
= 4.1 Hz), 2.45 (s, 3H); 13C NMR (CDCl3, δ ppm) 166.5, 145.0, 139.9, 130.6, 129.7, 127.7, 
119.0, 66.4, 35.8, 32.0, 21.5; IR (thin film, cm-1) 3077, 2969, 1734, 1638, 1158.  
The enantiomeric R-3a was also prepared in a similar manner from R-1b. 
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1-(p-Nosyl)-aziridine-2S-carboxylic acid allyl ester (3b). 3b was synthesised using a similar 
method to that used to synthesise 3a, except 4-nitrobenzenesulfonyl chloride (1.27 g, 5.4 
mmol) was used. The crude product was purified using flash column chromatography on 
silica gel in petroleum ether:ethyl acetate (4:1)  to yield 174 as a yellow oil (1.37 g, 80%). Rf: 
0.53 petroleum ether:ethyl acetate (2:1); [α]D20 = -64.28o (c 1.0 in CHCl3); 1H NMR (CDCl3, 
δ ppm) 8.41 (d, 2H J = 9.0 Hz), 8.22 (d, 2H J = 9.0 Hz), 5.90 (m, 1H), 5.28 (m, 2H), 4.64 (d, 
2H J = 5.8 Hz), 3.47 (dd, 1H J = 4.2, 4.2 Hz), 2.91 (d, 1H J = 7.1 Hz), 2.68 (d, 1H J = 4.2 
Hz); 13C NMR (CDCl3, δ ppm) 165.8, 150.9, 142.9, 130.8, 129.5, 124.5, 119.5, 66.8, 36.3, 
32.5; IR (thin film, cm-1) 3067, 2987, 1740, 1642, 1202 . 
The enantiomeric R-3b was also prepared in a similar manner from R-1b. 
 
1-(p-Nitrobenzyloxycarbonyl)-aziridine-2S-carboxylic acid allyl ester (3c). 3c was 
synthesised using a similar method to that used to synthesise 3a, except 4-nitrobenzyl 
chloroformate (1.16 g, 5.4 mmol) was used. The crude product was purified using flash 
column chromatography on silica gel in petroleum ether:ethyl acetate (4:1)  to yield 3c as a 
yellow oil (0.95 g, 82%). Rf: 0.49 petroleum ether:ethyl acetate (2:1). [α]D20 = -23.01o (c 1.0 
in CHCl3) (Lit. Value [α]D = -23.76o (c 1.0 in CHCl3))2; 1H NMR (CDCl3, δ ppm) 8.22 (d, 
2H, J = 8.8 Hz), 7.53 (d, 2H, J = 8.8 Hz), 5.89 (m, 1H), 5.37-5.27 (m, 4H), 4.62 (d, 2H, J = 
5.9 Hz), 3.22 (dd, 1H, J = 3.2, 3.2 Hz), 2.65 (dd, 1H, J = 1.2, 1.2 Hz) 2.57 (dd, 1H, J = 1.2, 
1.2 Hz); 13C NMR (CDCl3, δ ppm) 167.8, 160.2, 147.8, 142.4, 131.6, 128.4, 123.4, 119.1, 
66.8, 66.4, 34.9, 31.4; IR (thin film, cm-1) 3062, 2993, 1738, 1695, 1642, 1202. 
The enantiomeric R-3c was also prepared in a similar manner from R-1b. 
 
1-(Allyoxycarbonyl)-aziridine-2S-carboxylic acid allyl ester (7). 7 was synthesised using a 
similar method to that used to synthesise 3a, except allyl chloroformate (1.7 mls, 5.4 mmol) 
was used. The crude product was purified using flash column chromatography on silica gel in 
petroleum ether:ethyl acetate (4:1)  to yield 7 as a brown oil (0.39 g, 34%). Rf: 0.56 
petroleum ether:ethyl acetate (2:1); [α]D20 = -63.51o (c 1.0 in CHCl3); 1H NMR (CDCl3, δ 
ppm) 5.90 (m, 4H), 5.31 (m, 4H), 4.74-4.61 (m, 4H), 3.13 (dd, 1H, J = 3.1 Hz and J = 3.1 
Hz), 2.61 (dd, 1H, J = 1.3, 1.3 Hz), 2.50 (dd, 1H, J = 1.4, 1.3 Hz); 13C NMR (CDCl3, δ ppm) 
167.1, 156.9, 131.7, 131.2, 118.8, 118.5, 67.57, 67.51, 31.3, 29.7; IR (thin film, cm-1) 2957, 
1732, 1662, 1617. 
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N-(4-Methoxybenzyl)-2-nitrobenzenesulfonamide. 4-Methoxybenzylamine (0.34 g, 2.5 mmol) 
was dissolved in DCM (3 ml) and triethylamine (0.4 ml, 2.5 mmol). The mixture was cooled 
in an ice bath and o-nitrobenzenesulfonyl chloride (0.5 g, 2.3 mmol) was added portionwise 
over a period of 20 min. The mixture was then stirred at room temperature for 12 h. 1 M HCl 
(30 ml) was added and the solution extracted with DCM (2 x 30 ml). The combined organic 
layers were washed with brine (30 ml), dried over magnesium sulfate, and the solvent was 
removed in vacuo giving a brown oil. Recrystallisation from hexane:ethyl acetate (1:1) gave 
N-(p-Methoxybenzyl)-2-nitrobenzenesulfonamide as white crystals (5.8 g, 78%). Rf 0.53, 
petroleum ether:ethyl acetate (1:2); M.pt. 120-121 oC; 1H NMR (CDCl3, δ ppm) 8.01 (d, 1H, 
J = 9.0 Hz), 7.83 (d, 1H, J = 9.3 Hz), 7.69- 7.58 (m, 2H), 7.12 (d, 2H, J = 8.7 Hz), 6.75 (d, 
2H, J = 8.7 Hz), 5.63 (d, 1H, J = 12.0 Hz), 4.24 (d, 2H, J = 6.3 Hz), 3.75 (s, 3H); 13C NMR 
(CDCl3, δ ppm) 159.4, 148.0, 135.0, 133.3, 132.6, 131.1, 129.3, 127.6, 125.2, 114.0, 55.3, 
47.4;  IR (KBr, cm-1) 3308, 3021, 1540, 1364, 1158. MS (ES+) calculated for C14H14N2O5S, 
[2M+Na]+ 667.2, found [2M+Na]+ 667.2. 
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